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  II 
Abstract 
 
The increased use of mass spectrometry in the clinical setting has led to a demand for 
high sample throughput. Developments such as ultra high performance liquid 
chromatography and the ambient ionization techniques enable high sample throughput by 
reducing chromatographic run times or by removing the requirement for sample 
preparation and fractionation prior to analysis. This thesis assesses the reproducibility and 
robustness of these high throughput techniques for the analysis of clinical and 
pharmaceutical samples by ion mobility-mass spectrometry.   
The rapid quantitative analysis of the urinary biomarkers of chronic obstructive 
pulmonary disease, desmosine and isodesmosine has been performed by ultra high 
performance liquid chromatography combined with ion mobility-mass spectrometry. The 
determination of health status based on the free unbound fraction rather than the total 
bound and unbound desmosine and isodesmosine, significantly reduces the time taken in 
sample preparation.  
The potential for direct analysis of the urinary metabolites from undeveloped TLC plates 
using a solvent extraction surface sample probe is demonstrated. The use of a solvent 
gradient for the extraction separates urinary metabolites from salts and other matrix 
components and allows fractionation of the sample as a result of differential retention on 
the undeveloped RP-TLC plate. This separation, combined with ion mobility-mass 
spectrometry provides a rapid ambient ionization method for urinary profiling. 
The combination of a thermal desorption probe with extractive electrospray ionization 
has been applied to the direct detection of a known genotoxic impurity from a surrogate 
active pharmaceutical ingredient. The volatility of the impurity compared to the matrix, 
allowed selective thermal desorption of the analyte, which was ionized by extractive 
electrospray and detected by mass spectrometry. 
The use of a rapid on-probe derivatisation reaction, combined with thermal desorption is 
demonstrated for the direct determination of urinary creatinine. The aqueous acylation of 
creatinine significantly increases the volatility of the analyte enabling separation from the 
urine matrix and analysis by thermal desorption extractive electrospray combined with 
ion mobility-mass spectrometry.  
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Introduction 
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1.1. Clinical Analysis 
 
The early techniques employed for biomolecular quantitation in clinical laboratories were 
the wet chemistry methods based on colorimetric reactions which were used for the 
measurement of compounds in complex mixtures such as urine and blood. These methods 
enabled the measurement of numerous clinically relevant compounds including urea,
1
 
glucose
2
 and creatinine.
3
 The specificity and speed of the colorimetric techniques were 
subsequently enhanced by the incorporation of an enzyme catalysed reaction prior to the 
formation of a coloured complex. These simple methods for the colorimetric 
determination of compounds in complex mixtures are still standard clinical techniques for 
compounds of a sufficient concentration.  
The discovery of the radio immunoassay (RIA) by S.A. Berson and R.S. Yalow in 1959
4
 
provided the clinician with a sensitive tool for the detection of compounds at the 
picogram level. Detection and purification of target compounds by immunoassay was 
readily employed to thousands of analytes as specific antibodies (IgG) could be raised 
against any target epitope on an antigen from an animal or human source.
5
 The time 
required to raise the antibodies and small volumes of antigen specific antibodies 
obtainable from a living source increased the time taken to complete an investigation. 
These factors limiting antibody generation were removed by fusing the antibody 
producing B-cell lymphocytes from a mouse immunised against a specific antigen with a 
mouse myeloma cell line capable of producing antibodies. This technique discovered by 
Kohler and Milstein in 1975
6
 enabled the continuous generation of identical monoclonal 
antibodies that could be effectively harvested from a cultured cell line. The improved 
generation of antibodies from monoclonal cell lines promoted the development of the 
immunoassay technique with the replacement of the radio-labelled tag with luminescence 
tags (LIA)
7
 and enzyme reactions (ELISA).
8
 These approaches demonstrate a high degree 
of sensitivity and are capable of detecting picogram levels of an antigenic species, they 
can also be carried out at low cost using automated sampling systems with a typical cost 
of less than £2 per analysis. Due to these advances in the technology immunoassays have 
taken an important role in today’s clinical laboratory.   
  3 
The uses of immunoassays in clinical measurements are not without their limitations the 
primary problem that often arises is due to non-specific antigen binding events. The non 
specific binding of an antigen by an antibody occurs because the raised antibodies may 
display a binding region which is specific to a common chemical motif or epitope. For 
example, an antibody that was raised against the diazepine drug may also show a binding 
affinity with other members of the same class of compounds.
9
 Additionally interference 
may occur from compounds that compete with the antibody to bind the antigen. Finally 
the raised antibodies may be bound by anti IgG immunoglobulin in the sample matrix. 
All of these factors  can adversely affect immunoassay measurements and limit its 
quantitative potential.
10
 These limitations with immunoassay based measurements have 
promoted the use of mass spectrometry as a viable alternative for clinical applications 
which will be discussed in Section 1.1.1.  
 
1.1.1. Application of Mass Spectrometry in Clinical Analysis 
 
Mass spectrometry (MS) of small involatile biomolecules has been developed over a 
number of decades with early experiments taking place using field desorption (FD)
11
 and 
fast atom bombardment (FAB)
12
 ionization techniques. However these approaches were 
limited to lower molecular weight species, and in the case of field desorption difficult to 
perform and not very reproducible. The application of MS for biomolecular analysis was 
further enhanced by the introduction of electrospray ionization (ESI) by Fenn et al. 
1989
13
 and matrix-assisted laser desorption/ionization (MALDI) by Karas et al. in 
1985.
14
 These two new developments revolutionised biomolecular analysis by mass 
spectrometry and provide the clinician with a robust analytical platform with high 
sensitivity and specificity for the prognosis and diagnosis of medical samples. The use of 
MS has a number of advantages over the traditional clinical immunoassay based 
measurements. The primary advantage being the removal of non-specific binding events 
affecting the measurements as the determination of target analytes on the basis of their 
mass-to-charge ratio (m/z) allows the distinction between two compounds with similar 
structural motifs. Secondly the combination of MS with high performance liquid 
chromatography (HPLC) allows the separation of target analytes from a complex matrix, 
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enhancing quantitative determination of the analyte by separating them from background 
interferences. These improvements provided by LC-MS have seen increasing application 
in the clinical laboratory, usually as a definitive measurement which is performed after a 
point-of-care immunoassay screening procedure
15
 or as the replacement for the 
immunoassay entirely.
16
 
The use of MS in the pharmacological sector for the trace analysis of therapeutics has 
provided a wealth of small molecule and metabolite LC-MS applications. These 
techniques were further developed and have found application in the clinical toxicology 
environment, for the determination of performance enhancing compounds
17
 and drugs of 
abuse.
18
 The use of performance enhancing compounds in the sporting environment can 
provide an athlete with a significant advantage in relation to their competitors. The cases 
of intentional and unintentional ‘doping’ with steroidal based compounds have caused 
controversy in many athletic disciplines.
19
 The chemical modification of previously 
banned substances can generate new analogues from the original parent compound, 
which have similar physiological effects but are not regulated by international governing 
bodies. The application of MS for monitoring of athletes is now commonplace
20
 and the 
detection of steroidal metabolites in urine provides an effective deterrent against doping. 
The toxicological detection of drugs of abuse has also been affected by the process of 
chemical modification. Most countries have set laws on the drugs of abuse which only 
relate to a specific chemical structure. Minor modifications to these structures can 
generate a compound with similar physiological activity but with no legal ruling, that can 
be bought and sold without prosecution. These legal loopholes have enabled the rise of 
the chemical derivatives of illegal substances termed ‘legal highs’, which are now 
commonly abused with little or no knowledge relating to acute or chronic toxicity.
21
 The 
composition of the illegal substances purchased on the street has been shown to vary 
dramatically.
22
 These substances can contain adulterants that can induce unpredictable 
physiological effects on the user.
23
 High resolution full scan MS must be applied for the 
detection of unknown adulterants, as targeted MS based screening methods will not 
detect these substances.
24
 In both cases, MS can be used to provide compound and 
metabolite identification which can be used to guide clinical strategies. 
  5 
A clinical application where the use of MS has superseded immunoassays is in 
endocrinology, where the concentrations of hormones are determined in plasma and urine. 
These hormones may be present in the free unbound form at very low abundance (<10 
pg/mL), resulting in significant interferences observed in the hormonal immunoassay.
15
 
The routine analyses of testosterone,
25
 vitamin D,
26
 estradiol
27
 and thyroid hormones
28
 
have made the transition to MS-based measurements on the advice of the Endocrine 
Society.
29
 In the case of testosterone, more accurate measurements can be obtained using 
LC-MS/MS when compared to immunoassays as the isomers of dehydroepiandrosterone 
(DHEA) and epitestosterone can be separated by LC prior to MS analysis.
30
 Increased 
interest in the health benefits of vitamin D have resulted in the requirement of a serum 
based assay to determine the levels of the active 25-hydroxyvitamin D3 (25OHD3) and 
25-hydroxyvitamin D2 (25OHD2). The majority of the determination of these 
compounds was performed by LC-MS/MS as interference by protein binding can affect 
the regulatory approved immunoassays.
31
 The other commonly measured hormones, 
estradiol and the thyroid hormones are also transported around the body in a protein 
bound complexes.
32
 These complexes have little or no affinity for the raised antibodies in 
the immunoassays and measurements are restricted to the analysis of the low abundance 
free forms.
33
 
The application of LC-MS and LC-MS/MS over the traditional immunoassay in the 
clinical environment does have its limitations. Firstly to avoid any ion suppression of the 
target analyte or analytes, biological samples require sample preparation prior to analysis. 
These steps increase the time required for the analysis of the sample and therefore have a 
decreased throughput when compared to the immunoassay. The MS based analytical 
instruments are also expensive to purchase, require periodic maintenance and should be 
operation by suitably trained individuals only. The major limitation for the universal 
introduction of MS for clinical based analyses is that unlike the immunoassay, MS 
detection techniques lack regulatory validation. The MS detection methods though more 
specific and in some cases more sensitive than the corresponding immunoassay, are 
developed by individual laboratories and are termed laboratory developed tests (LDTs).
34
 
The operation of the MS instrument involves variables such sensitivity, resolution and 
calibration that generate discrepancies between laboratories inhibiting regulatory 
  6 
accreditation. The variables in the LTDs are being considered and the regulatory bodies 
are in the process of validating LTDs for clinical use that should allow normalisation of 
the techniques and the increased application of MS in this area in the future. 
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1.2. Ambient Ionization 
 
The area of ambient ionization, defined as the rapid ionization of samples/objects in their 
native state in the open environment
35
 is nearly a decade old following the work of 
Takats and colleagues on desorption electrospray ionization (DESI) which was first 
reported in 2004.
36
  Their findings have generated a new field in mass spectrometric 
analysis that removes lengthy sample preparation and chromatographic separation to 
allow measurements to be conducted in real-time.
37
 Currently over 30 individual ambient 
ionization techniques have been published,
38
 many of these techniques are modifications 
on the standard ionization methods of electrospray ionization (ESI) and chemical 
ionization (CI) (Table 1.1).  
A majority of the ambient ionization methods are hyphenated techniques that de-couple 
the desorption and ionization processes enhancing the application of the standard 
ionization methods to a greater range of analytes.  The ambient ionization techniques are 
generally low energy “soft” methods generating spectra comparable to ESI and CI with 
little or no fragmentation allowing for simple spectral interpretation. The applications of 
ambient ionization are as diverse as the number techniques with employment in 
pharmaceutical analysis and production,
39
 explosive detection,
40
 determination of 
pesticides
41
 and environmental pollutants
42
 and the ‘omic’ based profiling techniques of 
proteomics
43
 and metabolomics
44
. 
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Table 1.1. List of ambient ionization methods (reproduced from ref 
35
) 
Technique Acronym Introduced 
Desorption Electrospray Ionization DESI 2004 
Surface Sampling Probe SSP 2004 
Direct Analysis in Real Time DART 2005 
Atmospheric Solids Analysis Probe ASAP 2005 
Electrospray Laser Desorption Ionization ELDI 2005 
Fused Droplet Electrospray Ionization FD-ESI 2005 
Direct Atmospheric Pressure Chemical Ionization DAPCI 2005 
Matrix-Assisted Laser Desorption/Electrospray Ionization  MALDIESI 2006 
Jet Desorption Electrospray Ionization JeDI 2006 
Extractive Electrospray Sonization EESI 2006 
Desorption Sonic Spray Ionization DeSSI 2006 
Atmospheric Pressure Thermal Desorption/Ionization APTDI 2006 
Helium Atmospheric Pressure Glow Discharge Ionization HAPGDI 2006 
Plasma-Assisted Desorption Ionization PADI 2007 
Dielectric Barrier Desorption Ionization BDI 2007 
Neutral Desorption Extractive Electrospray Ionization ND-EESI 2007 
Laser Diode Thermal Desorption  LDTD 2007 
Laser Ablation Electrospray Ionization LAESI 2007 
Desorption Atmospheric Pressure Photo-Ionization DAPPI 2007 
Infra red Laser Ablation Electrospray Ionization IR-LAESI 2008 
Flowing Atmospheric-Pressure Afterglow FAPA 2008 
Easy Ambient Sonic Spray Ionization  EASI 2008 
Remote Analyte Sampling Transport and Ionization Relay RASTIR 2008 
Laser Ablation Flowing Atmospheric-Pressure Afterglow LA-FAPA 2008 
Low Temperature Plasma LTP 2008 
Desorption Electrospray Metastable-Induced Ionization DEMI 2009 
Liquid Micro-Junction Surface Sampling Probe/Electrospray 
Ionization  
LMJ-
SSP/ESI 
2009 
Surface Activated Chemical Ionization  SACI 2009 
Single Particle Aerosol Mass Spectrometry SPAMS 2009 
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1.2.1. Atmospheric Pressure Chemical Ionization (APCI) 
 
Chemical ionization (CI) is a well documented technique for the conversion of gas phase 
molecules into ions through formation of a reactant ion species which then donates its 
charge to the target analyte. In the case of atmospheric pressure chemical ionization 
(APCI), gaseous phase analytes are transported directly into the ionization region at 
atmospheric pressure. Samples in solution, such a HPLC mobile phase can be coupled to 
APCI using a high temperature gas nebuliser to volatilize the solvent and analyte 
molecules prior to APCI. Solid samples with sufficient vapour pressure may be desorbed 
directly into the APCI source.
45
 Unlike ESI ionization mechanisms, APCI requires no 
solvent flow (although a solvent or dopant flow can be used) and the generation of 
analyte ions is achieved through the use of a corona discharge.
46
 A corona discharge is 
initiated using a needle with a high potential applied, the high potential induces plasma 
formation through a corona discharge at the tip of the needle. The electric field emitted 
from the tip of the corona discharge needle into the ionization region causes ionization of 
the atmospheric nitrogen. Ion generation using a corona discharge is achieved by a series 
of charge transfer reactions resulting in the formation of a charged reactant ion. The 
reactant ion will transfer the charge onto an analyte molecule in the gas phase generating 
an ion. For the formation of positively charged analytes the processes are shown in the 
following series of equations.
45
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  
  eNeN 222       Equation 1.1. 
  2422 2 NNNN 

     Equation 1.2. 
  
  OHNOHN 2224 2      Equation 1.3. 
  
  OHOHOHOH 322     Equation 1.4. 
    222223 NHOHNOHOH 
    Equation 1.5. 
  OHHMOHM 23 
     Equation 1.6. 
 
The principle reactant ion formed for positive ionization is [(H2O)2H
+
]
+
 and is termed the 
reactant ion peak (RIP) in ion mobility spectrometry. The population of reactant ions is 
formed from a distribution of hydrated ions and therefore can be manipulated by altering 
the humidity of the ionization region. Further reactions of the reactant ions with water 
molecules leads to the formation of hydration clusters termed [(H2O)nH3O]
+
. The 
additional minor reactants ions [(H2O)nNH4]
+
 and [(H2O)n(NOx)]
+
 can also be formed 
within the ionization region. The formation of negatively charged reactant ions
47
 is a 
more complicated process than in the positive mode. The hydration (H2O), like positive 
mode ionization again plays a major role, with the [(H2O)nOH]
-
 as the major reactant ion.  
The use of APCI based ionization mechanisms is limited to gas phase molecules which 
can be volatilised by the APCI nebuliser. This limits the range of molecules amenable to 
APCI compared to ESI. The compatibility of the APCI ionization technique with 
involatile liquid and solid samples can be enhanced by a desorption step. These 
desorption steps include conventional heating termed thermal desorption (TD)
45
 or 
desorption by the use of a laser or plasma discharges.
48,49
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1.2.2. Electrospray Ionization (ESI) 
 
Ionization methods such as corona discharge based APCI are limited to the analysis of 
volatile and semivolatile compounds that can be effectively transferred to the gas phase. 
These methods, though efficient for the ionization of small, low molecular weight 
compounds, are not capable of efficiently ionising larger less volatile compounds such as 
biologically derived macromolecules. This limitation was overcome by Fenn and co-
workers in 1985,
13
 with their liquid based ‘soft’ electrospray ionization (ESI) method. An 
approach to ionization based on earlier work by Dole
50
 Fenn’s paper demonstrated the 
generation of singly and multiply charged ions from proteins with molecular weights in 
excess of 200 kDa. ESI along with matrix-assisted laser desorption/ionization (MALDI)
14
 
have since gone on to become the techniques of choice for the analysis of 
macromolecular species such as proteins,
51
 carbohydrates
52
 and polymers
53
 as well as 
small molecules. Figure 1.1 shows a schematic diagram of the electrospray ionization 
source. 
 
 
 
 
 
 
 
Figure 1.1. Diagram of an electrospray ionization source.
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In electrospray ionization, ions are created under ambient pressure by passing the analyte 
in solution through a capillary tube to which a strong electric field is applied (1-4 kV). 
The large potential difference between the capillary and counter electrode is applied over 
a small distance achieving strong electric fields of 10
6
 V m
-1
.
54
 Analyte species are 
ionized in solution typically by adding a volatile charge modifier to the sample solution 
e.g. formic acid for positive ions or ammonium to promote negative ion formation. The 
potential applied to the capillary induces the polarization of the ionized analytes at tip of 
the capillary forming a Taylor cone. The droplets ejected from the Taylor cone undergo 
solvent evaporation assisted by a co-axial flow of desolvation gas, to form the spray 
plume
63
 (Figure 1.2). 
 
 
Figure 1.2. Formation of the electrospray plume and the Taylor cone.
55 
  13 
The desolvation of solvent from an electrospray droplet reduces the droplet dimensions, 
whilst the ions carried within the droplet increase the charge to surface area ratio.  A 
equilibrium is formed when the forces of surface tension and ion repulsion within droplet 
are equal, termed the ‘Rayleigh limit’.56 Further solvent desolvation processes exceeding 
the Rayleigh limit induces droplet fission creating a fine mist of smaller charged droplets, 
this process is repeated through continuous desolvation until only gaseous ions remain. 
The mechanism in which gaseous ions are formed is still widely debated.
57
 For the 
formation of gaseous ions from the condensed phase two alternate models have been 
proposed the ion evaporation model (IEM)
58
 and the charge residue model
50
 (CRM) as 
shown in Figures 1.3 and 1.4. 
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Figure 1.3 and 1.4. ESI and the IEM and CRM models of ion generation.
57,55
 
Fig 1.3. 
Fig 1.4. 
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Under both IEM and CRM mechanisms, as a solvent droplet reaches the Rayleigh limit 
through desolvation it will undergo a number of fission events to form smaller droplets of 
approximately 10 nm in diameter.
59
 The IEM mechanism then depends on the shape of 
the droplet, which affects the distribution of the ionized molecules contained within. IEM 
postulates that if the ions within the molecule are unevenly distributed due to the droplet 
not being spherical, the contained ions may be in a close proximity to each other at a 
point on the surface of the droplet. The charge distribution in this particular area of the 
droplet could exceed the solvation forces and attempt to equilibrate the charge to surface 
area ratio by the liberation of ions into the gas phase. In the CRM model the distribution 
of ions within the solvent droplet is considered to be even and the model then predicts 
cycles of reaching the Rayleigh limit and subsequent solvent fission until each droplet 
contains a maximum of one analyte ion. The solvent droplet containing only a single 
analyte will then completely evaporate depositing a charge condensation on the now 
gaseous phase analyte. The condensed phase ESI process has advantages over the early 
gas phase ionization methods, as it allows the analysis of non volatile species but is also 
compatible with small molecules. A disadvantage of ESI is that ion suppression may be 
observed for complex samples as a result of competition for charge.
60
 Ion suppression in 
ESI may be overcome by pre-fractionation using high performance liquid 
chromatography (HPLC) and other sample clean-up techniques prior to MS 
measurements.  
 
1.2.3. Extractive Electrospray 
 
 The ionization technique of extractive electrospray (EESI) was first demonstrated by 
Chen, Venter and Cooks in 2006.
61
 This new ESI based technique employed two spray 
emitters positioned at ~90° relative to each other so that the spray generated from each 
emitter intersects in a ‘Y’ configuration in-line to the inlet of a mass spectrometer. The 
first of the two emitters carries the electrospray solvent (typically 50:50 organic 
solvent:H2O + charge modifier) under a high potential (5 kV) to induce polarisation of 
the electrospray phase to provide the charges necessary for ionization. The ionising spray 
may be nebulized by an N2 flow to aid formation of charged droplets. The second emitter 
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carries the sample in solution, which also is nebulized by a flow of N2 to form a spray, 
but the nebulizer is held at ground potential. The configuration of a typical EESI set-up is 
shown in Figure 1.5. 
 
 
 
Figure 1.5. Diagram of the EESI ionization technique.
61
 
 
Unlike ESI, where the analyte and other ions are polarised through the direct application 
of a high potential, analytes in EESI are ionised through the collision of a charged 
ionising droplet with a neutral droplet containing the analytes. This collision can cause 
the two droplets to interact or coalesce allowing a liquid-liquid extraction based 
ionization mechanism where the charge from the polarised mobile phase can be deposited 
in the neutral analyte containing droplet. The mechanisms behind EESI are discussed 
further in Section 1.2.2. 
Mobile Phase 
5 kV 
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EESI was shown to have significant advantages for the analysis of high salt containing 
solutions, such as urine, over the standard ESI techniques, with reductions in ion 
suppression effects and the stability of the analytical response over hours of analysis.
61
 
This improvement in analytical stability was attributed to the distribution of the analytes 
within the neutral droplet, where highly polar species reside in the centre of a droplet 
whilst the more non-polar analytes distribute themselves across the surface. In this 
distribution, surface-to-surface interactions with a charged solvent droplet would enable 
the majority of the non-polar compounds to transfer into the charged non-polar solvent 
environment allowing for selective ionization. Highly polar species such as the urinary 
salts will remain in the environment of the neutral droplet and therefore significantly 
reducing ion suppression effects.
62
 
A number of modifications have been made to the standard dual emitter for EESI 
analyses. The most common is the use of an ambient temperature gas flow (N2) to desorb 
analytes from a sample surface, as shown in Figure 1.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Diagram of a ND-EESI source (modified from ref 61). 
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The gas flow generates gaseous molecules from solid samples and micro-droplets from 
liquid samples which can be guided into a charged solvent spray for extractive ionization. 
This modification of the EESI technique is termed neutral desorption EESI (ND-EESI) 
first reported by Chen et al. in 2007 for the rapid non-invasive sampling of living 
objects.
63
 Other modifications include the ionization of the solvent spray via a corona 
discharge to improve the ionization efficiency of molecules with low proton affinity,
64
 
the use of non-polar solvents typically unsuitable for ESI
65
 and the modification of the 
MS inlet with an ion funnel for increased ion sampling efficiency.
66
  
 
1.2.3.1. EESI Mechanism 
 
The ionization mechanism behind EESI can be compared with other ambient ionization 
techniques, such as desorption electrospray ionization (DESI),
67
 secondary electrospray 
ionization (SESI)
68
 and fused droplet-electrospray ionization (FD-ESI).
69
 These ambient 
ionization techniques have a commonality in the interaction of a charged liquid with the 
neutral analyte via a liquid-liquid interaction or a gas phase charge transfer. The 
techniques of FD-ESI and DESI are both based on the interaction between charged and 
neutral droplets in the liquid phase, whereas in SESI analytes are desorbed using a N2 
flow and are transported to the ionization region in the gas phase with ionization 
occurring through gas-phase charge transfer of the vapour phase analytes into the ionising 
solvent droplets. In EESI, a number of factors including the difference in solubility 
between the sample and ionising droplets
62
 and the volatility of the analyte
70
 can 
significantly affect droplet interaction and ionization mechanisms.    
The mechanism of droplet ionization in EESI can be described by four alternate 
mechanisms; these mechanisms are depicted in Figure 1.7. 
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Figure 1.7. Possible liquid phase interactions in EESI.
71
 
 
The four possible mechanisms of interaction proposed in EESI describe the collision of 
the charged solvent droplet and a neutral sample droplet. These mechanisms describe the 
formation of a single larger droplet by ‘coalescence’, the collision and the refraction of 
the two droplets mixing the original droplets by ‘bounce’ or ‘disruption’ and the 
subsequent  formation of smaller droplet ‘fragments’. 
If we consider the process of droplet coalescence, where a mixture of the charged solvent 
droplet with the neutral analyte droplet is formed, this process would provide all the 
analytes contained within the neutral droplet an equal opportunity for ionization. This 
mechanism for ionization is not supported by the published experimental EESI data, as 
there would be no selectivity and the EESI technique would suffer from charge 
sequestering from the polar species within the droplet in the same manner as ESI (Section 
1.2.2). The lack of droplet coalescence in the mechanism of EESI was confirmed by 
Zenobi et al. (2012), who used phase dopplar anemometry (PDA) to determine that the 
relative size and density of the droplets did not increase post collision.
72
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The collision and subsequent refraction between the charged and neutral droplet can 
induce a number effects; ‘bounce’ in which an equal proportion of the two droplets are 
transferred to each other, ‘disruption’ relates to the disproportionate transfer of a 
proportion of one droplet to the other and ‘fragmentation’ where the collision of the two 
droplets generates smaller secondary droplets containing a mixture of both the charged 
droplet and neutral analyte droplet. In these methods, the selective transfer of analytes 
between droplets was found to be highly dependent upon the difference in analyte 
solubility between the neutral droplet and the charged droplet. These liquid-liquid 
interactions would provide the selective transfer of suitably soluble analytes from the 
neutral droplet into the charged environment, reducing the sequestering of charge and ion 
suppression by salts and other endogenous back ground species as observed in EESI 
experimental data.
61
 The three droplet interactions of bounce, disruption and 
fragmentation are all viable mechanisms for the selective liquid phase transfer of analytes 
as observed in EESI and would enable ionization along IEM and CRM electrospray 
mechanisms (as described in section 1.2.2) for the subsequent generation of gaseous ions. 
Additional PDA modelling by Wang et al. 2012
72
 also suggested that the fragmentation 
mechanism would be the major interaction between droplets. This could be tested by 
increasing the dimensions of the charged droplet in relation to the neutral droplet 
enhancing the formation of fragments, which would generate an increase in analyte 
sensitivity. 
An important area of ionization in EESI that the droplet interaction theories do not cover 
is the ionization of a gaseous analyte by charged droplets, which occurs in techniques 
such as SESI, neutral desorption EESI (ND-EESI) and thermal desorption EESI (TD-
EESI). In these extractive ionization configurations the ionization process can occur via 
two mechanisms as shown in Figure 1.8.  
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a) gas phase-gas phase interaction  b) gas phase-liquid phase interaction 
 
Figure 1.8. Possible interactions between neutral analytes in the gas phase (white) 
with a gaseous proton donor or charged droplet (black). 
 
The first mechanism describes a gas phase charge transfer of a charged reactive species 
with a neutral gaseous phase analyte. This gas phase-gas phase ionization process will 
occur via APCI mechanisms (as described in section 1.2.1), as the desolvation of the 
positively charged aqueous solvent droplet will eventually generate the production of 
protonated water clusters which are a strong proton donors. This contribution of a gas 
phase ionization process in EESI was demonstrated by Meier et al. 2011, where the 
ionization of a series of primary amines (1-butyl to 1-decylamine) where investigated. It 
was found that due to the volatility of the primary amines analysed the ionization process 
followed APCI mechanisms, equivalent to SESI, unlike less volatile compounds which, 
as described previously, showed a droplet fragmentation ESI process similar to FD-ESI.
70
 
The final method of gas-phase extractive ionization that requires consideration is the 
possible interaction between a neutral gaseous phase analyte with a charged droplet. In 
this method, gaseous analytes that are suitably soluble could enter the charged droplet 
allowing for an ESI based IEM or CRM ionization process following extraction into the 
droplet.  
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1.2.3.2. Applications of EESI. 
 
Since the development of EESI by Chen et al. 2006
61
 in excess of fifty papers have been 
published using the technique. The improvements in analytical sensitivity and stability 
for the analysis of high salt containing solutions using the EESI technique compared to 
traditional ESI has been described in Section 1.2.3. These improvements have enabled 
the application of EESI to biological based ‘omic’ investigations including the detection 
of native proteins
73
 and the manipulation of protein charge states.
74
 Investigations on 
amino acid
75
 and protein
73
 detection from within biological matrices such as urine have 
been reported. Urinary metabolomic studies have also reported for the detection of the 
herbicide atrazine,
76
 monitoring a patient’s dietary intake,77 bacterial metabolomics from 
cell extracts,
78
 and the direct quantitation of creatinine levels using the dual emitter 
configuration.
79
   
The original report of EESI refers to the application of the technique to beverages, which 
has lead to further publications in this area. micro-droplets can be obtained from a liquid 
by bubbling N2 through a solution or by ultrasonification, enabling EESI analysis of the 
droplets for the mass spectrometric fingerprinting of beverages
80
 and oils.
81
 The EESI 
technique has also been applied to the monitoring of contaminated milk,
82
 air pollution,
83
 
trace analysis of heavy metals in beverages
91
 and the detection of radioactive isotopes in 
the atmosphere,
92
 soil and water.
84
 EESI also has industrial applications enabling on-line 
reaction monitoring for active pharmaceutical ingredients (APIs).
85
 
The EESI technique is especially suited to the analysis of aerosols, as these gaseous 
phase droplets can be directly interfaced to the charged solvent plume for extractive 
ionization.
86–88
 The inherent compatibility has generated a range of medical based 
publications on the rapid profiling of exhaled breath
89–91
 and the targeted identification of 
exhaled metabolites relating to pharmacokinetics
92
 and narcotics detection.
93
 The analysis 
of cosmetics has also been performed with the fingerprinting of perfumes
94
 and the 
monitoring of the plastersizer levels used in the formulation of perfumes.
95
  
The hyphenation of extractive electrospray with a desorption process such as neutral 
desorption been used to analyse a wide range of compounds with specific application to 
the analysis of viscous liquids that cannot be effectively nebulized. Application of the 
  23 
ND-EESI technique includes the analysis of emulsified liquids and detection of illicit 
additives in cosmetic lotions and toothpaste.
74,96–99
 The non-invasive nature of ND-EESI 
has enabled the surface analysis of foodstuffs for the determination of food quality
100,101
 
and the analysis of skin for the detection of explosive residues.
102,103
 The combination of 
ND-EESI with travelling wave ion mobility (TWIMS) has been reported for the direct 
analysis of pharmaceutical APIs.
104
 
The hyphenation of EESI is not limited to neutral desorption with publications reporting 
the hyphenation of thermal desorption (TD) with EESI. The process of TD enables the 
selective analysis of compounds based upon their relative volatility. This process has 
been shown to enable the targeted analysis of volatile metabolites from biological 
matrices.
105
  
 
1.2.4. Ambient Ionization in Clinical Analysis 
 
The application of ambient ionization techniques to clinical analyses has been made 
possible by the introduction of atmospheric pressure ionization sources for mass 
spectrometry. These offer significant enhancements in analytical simplicity and 
throughput providing rapid real-time measurements to aid the clinician. The analysis of 
blood samples has progressed in recent years to the use of dried blood spots (DBS). 
These small volumes of samples can be easily stored at ambient temperatures for 
extended periods, whilst retaining their clinical significance. The DBS sample spots are 
extracted using an organic solvent and then analysed by LC-MS/MS.
106
 More recently, 
DBS have been analysed directly from the paper matrix techniques such as desorption 
electrospray ionization (DESI), direct analysis in real time (DART) and paper spray (PS) 
providing immediate clinical information. The majority of these ambient ionization 
techniques have been assessed for their ability to directly detect active pharmaceutical 
ingredients from the blood matrix using DESI
107
 and paper spray.
108
 However, more 
clinically relevant applications include the use of atmospheric pressure thermal 
desorption chemical ionization (APTD-CI) for lipidomic profiling
109
 which has been 
shown to alter due to disease onset. Additionally, metabolite profiling of ovarian cancer 
using DART
110
 and bladder and renal cancer using DESI
111,112
 has been performed from 
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DBS and tissue samples respectively. Ambient ionization techniques have also been 
applied to the direct analysis of urine for profiling by DESI
113
 and the quantitation of 
urinary components by EESI.
79
   
The application of ambient ionization has also made the transition to the surgical 
environment with the development of rapid evaporative ionization mass spectrometry 
(REIMS).
114
 In REIMS, the plume of ionized tissue generated from electrosurgical 
instruments is transported to a mass spectrometer allowing real-time profiling. The 
dissected tissue profile obtained is compared against a database of known healthy and 
disease tissues to provide the surgeon with an immediate indication on the health of the 
tissue without lengthy histological assessment. These approaches extend the application 
of ambient ionization to point of care clinical analyses. These ambient ionization sources 
are generally built in-house with only the DESI and DART sources available 
commercially, which leads to irreproducibility between laboratories using the same 
ambient ionization technique. These irregularities between laboratories require 
investigation and subsequent regulation, if the advantages of ambient ionization are to 
become authorised for clinical use or remain as a simple screening tool applied for 
research. 
 
1.2.5. Thermal Desorption 
 
The process of thermal desorption allows the generation of gaseous phase analytes from 
solid or liquid based samples through the application of heat. Appling a source of heat to 
a given sample will enables desorption of compounds based upon their relative volatility, 
which can be effectively combined with a GC or other gas-phase based analytical 
methods.  
 
1.2.4.1. Principles of Thermal Desorption 
 
Thermal desorption generates gaseous phase analytes by the heating of a sample, which 
enables the separation of volatile analytes from less volatile or involatile matrix 
components. For liquid samples this process is described using Henry’s law. 
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ckp H     Equation 1.7.  
 
Where p is the partial pressure of the solute in the gas phase, c is the concentration of the 
solute in solution and kH  is Henry’s law constant based upon constant temperature. 
 
Increasing the temperature applied to a solution increases the partial pressure of volatile 
compounds present in the solution, leading to the desorption of solutes on the basis of 
their partial pressures (i.e. volatility). The thermal desorption of analytes from solid 
surfaces that are chemically or physically adsorbed, can be lifted from a potential low 
energy state by the application of temperature, which can be described using the 
Arrhenius equation. 
 
RTE
d
dAek
/     Equation 1.8. 
 
Where kd is the desorption rate constant, A is the frequency of desorption, Ed is the 
desorption energy, R is the Boltzman gas constant and T is temperature.   
 
The rate of desorption or the rate at which an analyte molecule is liberated from the solid 
surface is dependent upon temperature. By increasing the temperature and maintaining all 
other factors the rate of desorption (kd) is increased. Individual analytes in a mixture will 
have different energies of desorption (Ed) that are required before desorption can occur. 
This demonstrates how separation of a mixture may occur using an increasing 
temperature profile.     
 
1.2.4.2. Applications of Thermal Desorption 
 
Thermal desorption has been used in a wide variety of applications, particularly in 
environmental monitoring. The environmental based analyses
115
 typically include 
measurements of known biologically toxic compounds in air,
116
 land
117
 and sea.
29
 The 
application of thermal desorption to biological liquids has been  demonstrated using the 
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stir bar sorptive extraction
 
(SBSE),
118
 which has been applied to a variety of biological 
fluids
119–121 
and solid phase micro extraction (SPME).
122,123
 In certain cases the volatility 
of a compound may be insufficient for analysis by thermal desorption in these 
circumstances specific derivatisation reactions can be performed in order to reduce the 
energy required for an analyte to partition into the gas phase. Thermal desorption has also 
been applied to the analysis of breath metabolites,
89
 where exhaled volatile organic 
compounds (VOCs) were trapped and concentrated onto an absorbent contained within a 
thermal desorption tube and analysed by GC-MS. These methods allow the fractionation 
of the complex biological samples and the removal of any interfering compounds by 
absorption to a surface prior to thermal desorption. Other applications have omitted this 
fractionation step and shown the direct analysis of compounds. These include the use of 
lasers for the thermal desorption process in laser diode thermal desorption (LDTD) for 
enzyme inhibition assays
124
 and the analysis of metabolites in plasma.
125
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1.3. Mass Analysers 
 
A wide range of mass analysers based upon magnetic and electric fields have been 
developed since J.J. Thomson first measured the mass-to-charge ratio of ions using a 
parabola mass spectrograph in 1913.
126
 These include the sector instruments discovered 
by Francis Aston,
127
 which were further developed by Alfred Nier and Arthur 
Dempster.
128,129
 The stability of ions under the influence of alternating electric fields by 
Wolfgang Paul produced the quadrupole and ion trap mass analysers.
130
 The time 
required for ions to transverse a field free flight tube held at high vacuum produced the 
time-of –flight mass analyser first postulated by W.E. Stephens.131 The separation of ions 
based upon their frequency of oscillation in magnetic field and an electric field cyclotron 
were devised by A.G. Marshall and A. Makarov respectively.
132,133
  
The work reported in this thesis was undertaken using a hybrid quadrupole time-of-flight 
mass spectrometer and supported by an electric field cyclotron (Orbitrap). This section 
describes these mass analysers in further detail. 
 
1.3.1. Time of Flight (ToF) 
 
Time-of-flight (ToF) mass spectrometry separates ions on the basis of the time required 
for an ion to transverse a drift tube under vacuum. The applicability of ToF for mass 
spectral analysis was first conceived by W.E. Stephens in 1946 who stated ‘in travelling 
down the vacuum tube, ions of different M/e have different velocities and consequently 
separate into groups spread out in space’.131 Linear and reflectron ToF analysers are 
described in this section. 
 
1.3.1.1. Linear ToF MS 
 
The first commercially available ToF MS system was based upon the system constructed 
by Wiley and McLaren.
134
 This simple linear TOF-MS system (LTOF-MS) was made 
from four distinct sections; a pulsed ionization region, an acceleration region, a flight 
tube and a detector as shown in Figure 1.9. 
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Figure 1.9. A linear ToF Mass Spectrometer.
134
 
 
Ions are introduced into the acceleration region in packets through the use of a pulsed 
ionization source or a Bradbury-Nielsen ion shutter. The ions are accelerated into the 
field free drift tube by a potential difference in the acceleration region. Ions accelerated 
into the flight tube all have approximately the same kinetic energy (Ek) after acceleration. 
The kinetic energy is determined by mass and the square of the velocity of an ion. 
 
2/2mvEk      Equation 1.9. 
 
Smaller ions will be accelerated to a higher velocity than heavier ions which will take a 
longer time to transverse the field-free flight tube. The charge state of the ion also effects 
flight time as highly charged species will be more affected by the accelerating voltage 
than lower charged species. The potential energy of an ion in the imparted on an ion 
within the acceleration region is equal to Ek after acceleration defined by 
 
SSk zeVqV
mv
E 
2
2
    Equation 1.10. 
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Where Ek is the kinetic energy, m is the mass of the ion, v is the velocity of the ion, q 
equals the total charge on the ion, VS is the electric potential difference through the ion is 
accelerated, z equals the number of charges on the ion and e is the fundamental unit of 
charge in coulombs (1.602 x 10
-19
).  
 
The velocity of an ion leaving the source region can be determined by rearrangement of 
equation 1.10 to  
 
  2/1/2 mzeVv S     Equation 1.11. 
 
The accelerated ion in a flight tube has a linear trajectory at a constant velocity and 
therefore the time taken for the ion to transverse the flight tube is 
 
v
L
t        Equation 1.12. 
 
Where t equals time and L equals length of the flight tube. Incorporating the equation for 
velocity into equation into 1.12 gives 
 







SeV
L
z
m
t
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2
2     Equation 1.13. 
 
This equation shows the relationship between m/z and the time-of-flight and the 
contribution due to the mass of the ion. Equation 1.13 can be rearranged to give 
 
t
L
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)/( 2/1    Equation 1.14. 
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1.3.1.2. Reflectron ToF 
 
The resolution achievable on a ToF based analyser is dependent upon the length of the 
flight tube and upon the ion arrival time distribution. In theory, when ions are accelerated 
into the field free region, ions of the same m/z should all have identical Ek values. In 
practice, there are differences in the Ek due to the positions of the ions in the accelerating 
region upon the application of the acceleration voltage. This distribution of Ek for the 
same m/z results in a range of arrival times and poor resolution for a linear ToF. This 
enhancement of resolution can be achieved by manipulating the ion flight path using an 
electrostatic reflectron. The refectron first devised by Mamyrin et al. in 1973 uses a series 
of ring electrodes with an electrostatic field to retard, focus and reflect the ion beam back 
through the flight tube
135
 (Figure 1.10).  
 
 
 
Figure 1.10. The electrostatic reflectron.
54
  
 
In the reflectron, the accelerated ions will penetrate into the electrostatic field and the 
extent of penetration is dependent upon the kinetic energy of the ion. In the case of two 
ions with the same m/z ratio where the first ion has high Ek and the second has a lower Ek. 
The high Ek ion will travel faster and penetrate further into the reflectron where higher 
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electrostatic fields are present. The high Ek ion will be repelled out of the reflectron with 
the same Ek as it entered but will have travelled a longer distance within the flight tube 
compared to the lower Ek ion. The resulting modification of the flight paths enables the 
simultaneous detection of both the high Ek and low Ek at the same time. The improvement 
in resolution results from a) effectively doubling the length of the flight of the fight tube 
and b) focusing the ion beam so that ions of the same m/z, but with different initial 
acceleration energies, arrive at the detector at the same time. Commonly reflectrons are 
configured off-axis to the entry ion beam so ions are propelled on an alternate trajectory 
towards the detector and not back towards the ion source. 
 
1.3.1.3. Orthogonal ToF MS 
 
The ToF mass analyser is commonly paired with pulsed ionization sources such as 
MALDI, since the pulsing of the ion source can be synchronised to the time required for 
the accelerated ions to transverse the flight tube and produce a response at the detector. 
However, this duty cycle between distinct ionization events can reduce instrument 
sensitivity when paired with a continuous ionization source such as ESI, as the ion gate is 
active whilst a packet of ions are in flight. The active ion gate will neutralise any ions 
from the ionization source until the previous packet of ions has been detected and 
recorded leading to significant ion loss and low sensitivity. 
The duty cycle of the ToF for continuous ion sources can be reduced by configuring the 
ToF tube orthogonally to the ion beam. The technique of orthogonal acceleration (oa-
ToF) first developed by O’Halloran and colleges in 1964 uses timed pulses of opposing 
potential to divert the ion beam into an oa-ToF tube. Acceleration of ions into the drift 
tube orthogonally to the ion beam from the source has the advantage of reducing the 
energy spread at the detector
136
 (Figure 1.11). 
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Figure 1.11. Reflectron ToF (modified from ref 
137
). 
 
The orthogonal acceleration of the continuous ion beam significantly improves the ion 
sampling efficiency of the ToF mass analyser when compared to a LToF system with a 
continuous ionization source.    
 
1.3.2. Quadrupoles. 
 
The quadrupole mass analyser first described by Paul and Steinwedel,
130
 separates ions 
based upon their stability under the influence of an oscillating electric field. Quadrupole 
mass analysers use four cylindrical rods positioned closely together arranged in a square 
with a gap through the centre to allow the passage of ions. The opposing metal rod pairs 
carry an alternating RF potential (V) which resonates between positive and negative, one 
pair of opposing rods is 180° out of phase with the other pair. A constant DC voltage (U) 
is superimposed on the RF to give the potentials tVU dc cos and 
Ion Source
Ion Focusing
Direction of 
Ion Beam
ToF Pusher
Reflectron
Detector
  33 
tVUdc cos applied to opposing rods. A schematic of a quadrupole is shown in 
Figure 1.12. 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. A quadrupole mass analyser.
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An ion with a positive charge passing through the quadrupole will be attracted towards 
one of the rods which has a negative potential applied and will drift towards it. Since the 
RF waveform is alternating the negative potential will change to a positive potential 
before the ion collides with the rod and will repel the ion towards one of the other pair of 
rods. Ions therefore, describe a complex spiral trajectory through a quadrupole. 
Quadrupoles operated using only the RF potential without any applied DC voltages will 
allow all ions to pass through the quadrupole with a stable trajectory, in this mode 
quadrupoles can be used to transport ions as an ion guide, or used as a collision cell 
(when filled with a collision gas). To use the quadrupole as a mass analyser it is 
y 
z 
x 
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necessary to superimpose a DC potential to the quadrupole rods. This selectively causes 
ions of different m/z to have a stable trajectory through the quadrupole. The stability of an 
ion in a quadrupole can be determined mathematically using the Mathieu equation: 
 
  02cos2/ 22  uqadud u       Equation 1.15. 
 
Where u = x or y and ξ = π ft (f = frequency, t = time), the terms of a and q relate to the 
DC and RF potentials respectively.  
 
The stability of an ion on the x and y axis is determined by the Mathieu au and qu 
parameter which can be derived from equation 1.15. 
 
22/8  oyx mreUaa     Equation 1.16. 
 
22/4  oyx mreVqq     Equation 1.17. 
 
Where m equals the mass of the ion, r0 is the radius of the quadrupole operated under the 
RF and DC potentials. The au and qu parameters of the Mathieu equation can also be 
represented in the form of a stability diagram (Figure 1.13) which is a graphical 
representation of the stability of an ion across a range of DC and RF potentials. An ion in 
a quadrupole field has a ‘working point’ in the stability diagram determined by its a and q 
values. 
 
 
 
 
 
 
 
 
  35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. A representation of a stability diagram of an ion. 
 
For an ion to be transmitted through the quadrupole it must have a stable resonance in the 
x and y axis. Operating in RF-only (V) mode, the working point of all ions will be on the 
x-axis of Figure 1.13. Increasing the DC voltage applied to the rods will move the ion in 
the U (y-axis) direction. Quadrupole mass spectrometers select ions by ramping both the 
DC and RF voltages so that ions follow the scan line depicted in the diagram. As the 
potentials increase, the ions move up the scan line and pass through the transmission 
points for low to high m/z ranges at the apex of the stable region. This transmits each m/z 
in turn, acting as a mass filter. This method of quadrupole mass selection is termed mass-
selected stability. 
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1.3.3. Orbitrap 
 
The orbitrap mass analyser devised by Makarov in 2005
133
 is a new method of ion 
separation based upon the Kingdon trap
138
 developed in the 1920s. The instrument uses a 
barrel shaped outer electrode and a spindle shaped inner electrode.  A DC potential (~3 
kV) is applied to the spindle electrode whilst the barrel electrode is grounded, a diagram 
of the orbitrap is shown in Figure 1.14.  
 
 
 
Figure 1.14. Diagram of the orbitrap mass analyser.
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A gap in the barrel electrode allows the injection of high velocity ions (1600 eV) into the 
space between the barrel and spindle electrodes. The injected ions become attracted to the 
opposing potential of the spindle electrode, but due their inherent kinetic energy 
centrifugal forces inhibit collision and the ions begin to oscillate around the central 
spindle. Ions of different m/z will have oscillation frequencies that can be determined by 
the equation below. 
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 kmq /     Equation 1.18. 
 
Where ω is the angular frequency of oscillation, q is the total charge of the ion, m is the 
mass of the ion and k is the constant DC potential. 
 
The injected ions will move back and forth along the central spindle with an oscillating 
frequency determined by their q/m ratio (Equation 1.16.). The ion motion is detected by 
the image current induced on the outer electrode that generates a unique oscillating 
waveform for each m/z that can be converted into a mass spectrum by Fourier 
transformation. Orbitraps have high mass resolution since the frequency of oscillation is 
used to determine m/z, which can be measured more accurately then arrival time.  
 
Table 1.2. Compares the performance of quadrupole, ToF and Orbitrap mass 
analysers (modified from ref 
54
). 
 Quadrupole ToF (refectron) Orbitrap 
Mass Limit 
(Th) 
4000  >1000,000 (10,000) 5,000 
Resolution          
(m/z 1000) 
2000 5000 (20,000) 100,000 
Accuracy  
(ppm) 
100 200 (5) <5 
Ion Sampling 
Method 
Continuous Pulsed  Pulsed  
 
1.3.4. Hybrid Instruments 
 
Hybrid instruments combine two separate mass analysers in a single instrumental 
platform. These instruments are principally used for tandem mass spectrometry 
experiments (MS/MS).  Improved selectivity, sensitivity and resolution can be achievable 
in comparison to the use of a single mass analyser. The most common combinations are 
the hyphenation of a mass analyser with mass-selection capabilities, using a quadrupole, 
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with additional quadrupole mass analysers or an analyser providing high resolution such 
as a ToF. The two analysers are separated by a region where fragmentation of mass-
selected ions can occur (see section 1.3.2). Of these hybrid instruments the combination 
of a quadrupole and a reflectron ToF (Q-ToF) was used in the work reported in this thesis. 
A schematic diagram of a Q-ToF spectrometer is shown in Figure 1.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15. A Schematic diagram of a Q-ToF instrument (modified from ref 
139
). 
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The Q-ToF hybrid instrument allows the selective transmission of an ion by mass-
selected stability in the quadrupole (see section 1.3.2) with the high resolution and mass 
accuracy of the reflectron ToF (see section 1.3.1.3.). The accurate ToF mass 
measurement of the fragment (daughter) ions generated from the collision induced 
dissociation (CID) of a mass selected ion provides the analytical chemist with a powerful 
method for the isolation, identification and structural characterisation of the original 
parent ion.  
The Orbitrap mass analyser has also been hybridised with a quadrupole in the Q-Exactive 
(Thermo-Fisher Scientific) for MS/MS analyses and a linear ion trap in the Velos Pro for 
MS
n
 analyses. Due to its non destructive method of mass analysis (described in section 
1.3.3) the ions can be directed out of the cyclotron post full scan high resolution 
measurement into a secondary mass analyser (quadrupole or ion trap) where an individual 
ion can be selected and fragmented before returning into the cyclotron for a second high 
resolution measurement of the fragments. 
 
1.3.5. Ion Detectors 
 
In a mass spectrometer or an ion mobility spectrometer the detection of an ion and the 
transfer of the signal generated from ion collision is performed by the ion detector. One 
of the most basic forms of detector which is still in common use is the ‘Faraday cup’, 
named after Michael Faraday, which was first used for MS in the 1930’s. The Faraday 
cup ion detector is simply a cylinder held at an opposing potential to the charge of the 
ions generated at the ionization source. The electrical current across the metal plate is 
measured by an electrometer, when the ions of opposing charge collide with the plate 
they generate a measurable signal based upon the relative abundance of colliding ions. 
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Figure 1.16. Schematic of a Faraday Cup.
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The neutralisation of an ion in the Faraday cup by collision of the ion with the plate may 
also causes the emission of secondary electrons that collide with the walls of the Faraday 
cup and discharge generating a signal. The Faraday cup has very low sensitivity as one 
neutralisation event produces only a small change in the overall current of the Faraday 
cup which requires further amplification. 
To enhance the sensitivity of the ion detector, electron multipliers were developed and 
are the most commonly used point detector for quadrupole, ion trap and magnetic sector 
mass spectrometers. Electron multipliers amplify the electron signal from a single ion 
neutralisation event using a series of discrete dynodes or a continuous dynode. In the 
electron multiplier an ion is accelerated towards an electrode called the conversion 
dynode which is held at a high opposing potential (~5 kV). The dynode has a special 
semiconductive coating, which when an ion collides with it releases one or more 
electrons. Electrons formed at the dynode are then drawn down the multiplier tube by an 
opposing potential gradient (high to low) as shown in Figure 1.17. 
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Figure 1.17. An electron multiplier.
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The collision of an electron with each dynode will generate a further two electrons which 
will continue down the multiplier. This cascade effect exponentially increases the number 
of electrons from a signal neutralisation event, resulting in approximately 10
6
 electrons 
for each ion neutralised. Single electron multipliers are useful as point detectors where 
ions are focused out of a device like a quadrupole or and ion trap. However, in a ToF 
mass analyser the beam may arrive over a wider area and to deal with this, the electron 
multiplier is multiplexed to form an array detector termed a microchannel plate (MCP). A 
MCP detector is circular disk (~5mm) that is few millimetres thick with channels bored 
through. A potential gradient is applied across the input and output sides. Ions will enter 
the channels input side of the MCP and become neutralised and emitting secondary 
electrons which will be multiplied by further collisions down the potential gradient. At 
the end of each channel in the MCP is an individual metal anode allowing the 
simultaneous measurement of ions arriving at different points on the array detector. 
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1.4. Hyphenated Techniques for Mass Spectrometry 
 
The separation of samples based upon m/z solely can be insufficient for the complete 
resolution of all the analytes from within the mixture. This is especially the case when 
analysing the biofluids of blood and urine which not only contain a wealth of compounds 
but also contain molecules with the same m/z but alternate structures that would not be 
resolved by mass analysis alone. To enable the resolution of complex mixtures and 
isomeric compounds additional separation techniques such as chromatography and ion 
mobility are hyphenated to mass analysis. 
The techniques of gas chromatography (GC) and liquid chromatography (LC) separate 
analyte mixtures based upon a compounds interaction with a stationary phase under the 
influence of temperature or concentration of organic solvent. Ion mobility enables the 
separation of compounds based upon their drift time through a drift region under the 
influence of an opposing drift gas. The combination of sample pre-separation prior to a 
mass analyser can isolate compounds in a mixture enhancing the analytical data that can 
be obtained at the cost of extended sample preparation steps and increased sample 
analysis times. 
 
1.4.1. Liquid Chromatography 
 
In high performance liquid chromatography (HPLC) analytes are dissolved in a mobile 
phase that is passed through a column packed with particles, usually spherical silica or 
styrene divinylbenzene beads, termed the stationary phase. Compounds in the mobile 
phase interact with the stationary phase through non-covalent interactions. The most 
widely used HPLC technique used today is termed reversed phase HPLC (RP-HPLC), 
which uses a polar mobile phase usually methanol:water or acetonitrile:water, and a non 
polar stationary phase. Reversed phase stationary phases typically consist of silica beads 
that are covalently bound to straight chain alkyl groups. Octadecyl silane (C18) is the 
most popular phase for RP-HPLC, although other phases such as C8 and C2 are useful 
for analysing larges molecules, such as proteins, and phenyl phases are useful for the 
analysis of aromatic compounds. Analytes in the polar mobile phase will interact with 
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these alkyl chains as they pass through the column. The extent of the interaction of an 
analyte molecule with the alkyl chains will depend upon the polarity of the molecule. 
Non-polar compounds will have greater interactions than polar species leading to the 
fractionation of complex mixtures. The fractionated compounds are sequentially eluted 
from the HPLC columns using mobile phase gradients from a polar mobile phase to a less 
polar mobile phase by increasing the percentage of organic solvent in the mobile phase 
e.g. H2O to MeCN. 
The efficiency of a chromatographic separation was first defined by Martin and Synge,
140
 
who suggested that the length of the column could be divided into separate sections, 
which were termed ‘theoretical plates’ (Equation 1.19). 
 
2
16 


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


b
r
w
t
N     Equation 1.19. 
 
Where N is the number of theoretical plates, tr is the retention time of the analyte and wb 
is the peak width at the base.  
 
Within each theoretical plate a mixture of compounds in solution will distribute 
themselves between the mobile phase and stationary phase according to the compounds 
partition co-efficient forming an equilibrium. The more theoretical plates a column has 
the greater the efficiency and chromatographic performance. However the efficiency of 
an LC separation changes with the mobile phase flow rate, if equilibrium is not achieved. 
This occurs due to non-equilibrium effects and the contribution of the effects on the 
efficiency of a chromatographic separation can be determined by the Van Deemter 
equation. 
 
uCuCuBAH most  /    Equation 1.20. 
 
Where H equals the height equivalent to a theoretical plate (L/N) for a column of length L, 
A is determined by Eddy diffusion, B relates to longitudinal diffusion, C relates to non-
equilibrium mass transfer between the phases and u equals the mobile phase flow rate. 
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The A term is determined by the flow paths of compounds through the column which is 
affected by the size of the stationary phase particles and uniformity of the column 
packing, determined by 
 
pdA .     Equation 1.21. 
 
Where λ equals the column packing uniformity and dp equals the particle size of the 
stationary phase.   
 
The B term in the Van deemter equation relates to the longitudinal diffusion of a 
compound from a region of high concentration to regions of low concentration that can 
be determined by 
 
mDB .2     Equation 1.22. 
 
Where γ relates to a hindrance factor caused by the packed stationary phase and Dm 
relates to the diffusion coefficient of the compound in the mobile phase.  
 
The Cst term relates to the mass transfer of a compound from the stationary phase to the 
mobile phase which can be calculated by 
 
stfst DdC /
2
    Equation 1.23. 
 
Where df relates to the thickness of stationary phase on the silica particle and Dst is the 
compounds diffusion coefficient in the stationary phase.  
 
The final term Cmo relates to the mass transfer of a compound from the mobile phase to 
the stationary phase that can be determined by 
 
mpmo DdC /
2
    Equation 1.24. 
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Where dp equals the diameter of the stationary phase particles and Dm is the compounds 
diffusion coefficient in the mobile phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18. A Van Deemter plot showing the effects of the A, B and C terms on the 
height equivalent to a theoretical plate. 
 
In HPLC columns, the diameter of the stationary phase particles is typically 5 µm, but the 
efficiency of the chromatography can be improved by reducing the stationary phase 
diameter, which has resulted in the development of ultra high performance liquid 
chromatography (UHPLC). In UHPLC, the diameter of the particle size is reduced to 1.7 
µm, this affects the A and the Cmo terms of the Van Deemter equation resulting in the 
reduction of the height equivalent to a theoretical plate and improving efficiency at the 
expense of higher back pressures (~13,000 psi). Specialist UHPLC systems such as the 
Waters Aquity are required for the 1.7 µm particle size column. However, due to the 
Mobile Phase Velocity/ cm s-1) 
H
eig
h
t eq
u
iv
alen
t to
 a T
h
eo
retical p
late
 
  46 
higher efficiency, chromatographic run times with UHPLC are much faster (typically <5 
min) than standard HPLC runs. 
 
1.4.2. Ion Exchange Chromatography 
 
Reversed phase HPLC is limited by the interaction of an analyte with the stationary phase 
and this limits the use of the non polar C18 stationary phase for the analysis of 
compounds with ionic and polar functional groups, which have limited interaction and 
retention on the chromatographic column. The separation of polar compounds can be 
achieved using unbonded silica particles or silica with immobilised polar functional 
groups. These techniques, termed normal phase chromatography due to the polar 
stationary phase in relation to the less polar mobile phase, have given rise to hydrophilic 
interaction chromatography (HILIC) and ion exchange chromatography (IXC). 
In IXC, mixtures of ionic compounds can be separated based upon their affinity for an 
anionic or cationic stationary phase. In cation exchange chromatography, positively 
charged analytes interact with the negatively charged stationary phase typically sulfonic 
or carboxylic acids whilst alternatively, in anion exchange chromatography, negatively 
charged analytes interact with the positively charged stationary phase such as quaternary 
ammonium compounds. The cationic and anionic stationary phases used in IXC are each 
divided into two groups termed strong and weak dependent upon the type of functional 
group bound to the silica particles. The equations relating to cation (Equation 1.25) and 
anion (Equation 1.26) exchange are given below. 
 
  XYR    YXR    Equation 1.25. 
 
  XYR    YXR    Equation 1.26. 
 
Where R the immobilised stationary phase ligand, Y is the analyte and X is the competing 
counter ion.  
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Upon injection to a cation exchange column positively charged analytes will form 
coulombic interactions with the anionic stationary phase displacing the counter ion 
already present (e.g. H
+
). Gradient elution can be accomplished by increasing the 
concentration of an eluting cation such as Na
+
 in the mobile phase. The eluting cation 
will compete for the available binding sites on the anionic stationary phase. This will 
cause the exchange of the analyte ion for the eluting cation and therefore the analyte will 
be released from the stationary phase and pass into the mobile phase resulting in elution 
from the chromatographic column. By increasing the concentration of the eluting cation 
analytes can be eluted in order of their ionic strength. The same method of analyte elution 
occurs in anionic exchange chromatography, but the bound negatively charged analytes 
are eluted from the column with increasing concentrations of an eluting anion such as Cl
-
. 
The technique of ion exchange chromatography has limited use in mass spectrometry due 
to the high levels of salt used during separation process and IXC columns are typically 
connected to electrochemical and UV detectors. The  involatile salt content in the column 
effluent will inhibit ionization processes as the salt clusters within the liquid sequester the 
charge used to ionise the contained analytes in a process termed ‘ion suppression’.68 
Involatile salts also precipitate out in ESI sources resulting in degraded instrument 
performance. These suppression effects can be reduced by the use of post column 
membrane suppressors, which interact with the eluent to remove the nonvolatile salts and 
reducing the ion suppression effects. 
 
1.4.3. Ion Mobility Spectrometry 
 
The past three decades have seen and ever increasing interest in ion mobility (IM) 
measurements for the isolation of specific compounds from complex mixtures in the gas 
phase. IM is a fast and reproducible analytical technique for the separation of ions based 
upon their collisional cross section (Ω), i.e. size and shape,141 and is used daily in the 
security and military sectors for the rapid and sensitive detection of explosives, chemical 
warfare and narcotic agents.
142 
A description of the behaviour of gaseous ions within a 
weak electric field was first derived by Mason and Schamp in 1958.
143
 The Mason-
Schamp equation, combined with Mason & McDaniels gaseous ion collision theories,
144
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resulted in the development of IMS for the separation and characterisation of chemical 
compounds. This interest, combined with advances in engineering, saw the extensive 
miniaturization and hyphenation of IMS instruments from bench size systems to portable 
handheld device enabling on-site monitoring of trace VOCs. 
 
1.4.3.1. Drift tube Ion Mobility Spectrometry 
 
A basic schematic diagram of an ion mobility (IM) drift cell is shown in Figure 1.19. 
 
Figure 1.19. Schematic of a IMS drift cell.
142
 
In a simple IMS instrument, gaseous phase analytes are generated in the ionization region 
are held by a gate that regulates the entrance of ions into the drift region by the 
application of an appropriate potential.  Once the potential on the ion gate is removed a 
‘packet’ of ions enters the drift region. The ions within the drift region move under the 
influence of an applied electric field and undergo a number of collisions with the 
opposing flow of drift buffer gas. The collisions separate mixtures of ions based on their 
gas phase ion mobility. The resolved ion mixture is detected at the end of the drift tube 
using a Faraday plate. 
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1.4.3.2. Ion Mobility Theory 
 
The principles of ion mobility characterisation are based upon the gas phase mobility (K) 
of an ion through a drift region at ambient/reduced pressure, in the presence of a drift gas 
and under the influence of an electric field gradient (E). In most IM instrumental 
configurations, the electric field is typically 10-200 Vcm
-
1, depending on the pressure of 
the drift gas. The momentum of the ions within a drift region is dissipated by collisions 
with the drift gas (usually air or nitrogen) resulting in a directed diffusion of ions through 
the drift cell. Under these conditions, the separation of ions depends on their drift time 
(td), which is related to ion velocity (Equation 1.27). 
KEv     Equation 1.27 
Where v is the velocity of the ion through the drift region, which is defined by the ion 
mobility K and the electric field gradient E. 
The mobility of an ion within any given drift cell is related to the collision cross section 
(Ω) of the ion, based upon the number of interactions the ion experiences within the drift 
region, defined by the Mason-Schamp equation (equation 1.28). 
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    Equation 1.28. 
Where q represents the ion charge state, N is the number density of the drift gas, k is the 
Boltzman gas constant, μ is the reduced mass (kg) and Teff  is the effective temperature, Ω 
represents the collision cross section of the ion and α is the electric field correction factor.  
Ion mobility is dependent upon the experimental conditions and types of instrument used. 
For example, ion mobility depends on the E/N ratio and equation 1.28 only holds under 
low field conditions (<2-10 Td). The same applies to investigations carried out at 
differing temperatures (Teff). In order to compare ion mobility measurements obtained 
under differing conditions and employing alternate instruments, mobility is usually 
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reported as reduced mobility (Ko) which normalizes the data for temperature and pressure 
and as shown in equation 1.29. 
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   Equation 1.29. 
Where d is the length of the drift region (cm), t is the drift time of the ion (s), E is the 
electric field gradient (Vcm
-2
), p is the pressure of the drift tube (in torr) and T is the 
temperature (in Kelvin). 
At a constant pressure and temperature, the most important factors within the Mason-
Schamp equation are the ion charge state (q) and the collision cross section (Ω). This 
permits the use of ion mobility measurements for structural elucidation through the 
measurement of collision cross sections and the separation of structural isomers and 
conformers on the basis of charge state and Ω.145 
 
1.4.3.3. Travelling Wave Ion Mobility 
 
Unlike conventional mobility drift tubes that use a constant electric field for the 
propulsion of ions. Travelling wave ion mobility spectrometers employ a series of 
stacked ring ion guides (SRIG) first described by Bahr et al in 1969.
146
 A schematic of a 
SRIG is shown in Figure 1.20. 
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Figure 1.20. The stacked ring ion guide.
147
 
 
The SRIG allows the transport of ions much like a quadrupole operated in RF only mode 
(see section 1.3.2). However, the SRIG uses as series of planar ring electrodes stacked 
orthogonally to the ion beam, with a sequence of opposing phase RF voltages applied to 
consecutive rings.
147
 The opposing phases generate a radial field that focuses the ion 
beam, which can be enhanced by decreasing the internal aperture to generate an ion 
funnel.
148
 The potential applied in a SRIG generates an ‘ion pipe’ where the confining 
field is low in the centre of the aperture, but rises rapidly if the ions trajectory is towards 
the walls of the electrodes. The segmented nature of the SRIG generates an oscillating 
axial confining field due to the gaps between the individual electrodes, unlike the 
symmetrical fields generated in a quadrupole, which can cause ions to become trapped 
within the ion guide. To negate the potential for axial ion trapping SRIG employ a 
superimposed axial DC potential that is generated between electrode pairs that is passed 
in sequence across the SRIG. This superimposed potential is termed the travelling wave 
and is depicted in Figure 1.21.  
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Figure 1.21. a) The RF confining fields in a travelling wave in stacked ring ion guide, 
b) movement of the travelling wave down the SRIG and c) separation of ions based 
upon their mobility in relation to the travelling wave and the opposing flow of drift 
gas.
149
 
 
 
 
 
  53 
The travelling wave is essentially a potential generated by the superimposed DC voltage, 
which is separated by five electrode pairs, that pushes the ions down a potential gradient 
and through the SRIG. This additional energy minimises the time an ion spends within 
the ion guide. The travelling wave DC potential is higher closer to the walls of the 
electrode aperture which repels ions into the centre aiding ion focusing. 
The effect of introducing a neutral buffer gas into the SRIG, allows the device to act as an 
ion mobility spectrometer. In the presence of the gas, the transport of an ion across the 
SRIG is dependent upon the travelling wave height (V), velocity (m/s) and gas pressure 
(mbar). If the velocity of the wave and gas pressures are kept constant ion simulations 
show the effect of wave height on the transmission of an ion.
147
 Alteration of the wave 
height can cause three events; with no travelling wave an ion can become trapped in the 
axial potential, with a large wave potential an ion ‘surfs’ the decreasing potential gradient 
to the exit of the SRIG at the speed of the travelling wave. However, with an intermediate 
wave height, the ion will surf along the decreasing potential gradient, but interactions 
with the neutral buffer gas will result in ‘drag’, causing the ion to roll over the top of the 
wave. This process of interaction and drag provides a mobility based separation of ions in 
the SRIG termed travelling wave ion mobility spectrometry (TWIMS). 
In TWIMS ions with a high mobility in relation to the travelling wave will be constantly 
propelled at the base of a travelling wave through the SRIG, ions with a lower mobility 
will roll over the top of the travelling wave more frequently and will be propelled through 
at a lower velocity by subsequent travelling waves. This separation of the ions based 
upon the ions interaction or collision with the neutral buffer gas provides information on 
the structural characteristics (i.e. size and shape) of an ion. This is because smaller ions 
with a compact structure will have a lower collision cross section for interactions with the 
buffer gas than compared larger ions with a larger collision cross section. This type of ion 
mobility has been commercially available in the Synapt HDMS instrument manufactured 
by Waters which was used in the experimental work described in this thesis (Figure 1.22). 
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Figure 1.22. A diagram of the Synapt HDMS system.
149
 
 
The Synapt HDMS system uses three SRIGs in the TriWave cell, these are termed the 
Trap, IMS and Transfer cells respectively and are shown in Figure 1.23. 
 
Figure 1.23. The Waters Synapt HDMS TriWave (Trap, IMS, Transfer) cell.
149
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In the TriWave cell, ions from the ion source entering the Trap SRIG are focused using 
the RF radially confining field and can be held within the trap using a DC potential wall 
applied across the final two electrodes. Once the DC potential is removed a ‘packet’ of 
ions will exit the trap and enter the IMS cell and undergo separation based upon the 
mobility of the ions under the influence of the travelling wave as described previously. 
As the packet of ions leaves the trap the DC wall potential is reapplied and a new packet 
of ions are accumulated from the ion source. This decreases the duty cycle due to the 
mobility separation. The mobility resolved ions are moved into the Transfer SRIG where 
the travelling wave is maintained but no buffer gas is present. This retains the separation 
in the mobility dimension, whilst transporting the ions to the orthogonal refectron ToF 
mass analyser for an additional separation on the basis of mass-to-charge ratio. 
The application of TWIMS for research can be grouped into two separate categories; a 
short overview of both will be described. The first general type of TWIMS research is the 
determination of the ion mobility of a mass-selected ion or ions. In drift tube IMS 
systems with a static electric field gradient, ion mobility is directly related to the ions 
collision cross section (CCS) as described in section 1.4.3.2. However, in a travelling 
wave in TWIMS the relationship between drift time and collision cross section is more 
complicated as additional kinetic energy is imparted on the ion. Therefore, to overcome 
this issue a TWIMS requires calibration using a series of known standards that have 
known CCS measured on a static field IMS cell, using helium buffer gas. There have 
been many different standards used for the calibration of the TWIMS cell including 
tetralkyl ammonium halides (TAAHs)
150
, peptides,
151,152
 and proteins.
153
 The accurate 
collision cross sections of carbohydrates
154
 and oligonucleotides
155
 have also been 
determined and could be employed as additional TWIMS calibration compounds. The 
type of TWIMS calibrant selected for use will depend upon the structural characteristics 
and mass range of the target analytes that are being measured. CCS measurements have 
been applied to structural studies of metabolites,
156,157
 glycans,
158
 oligonucleotides,
159
 
lipids,
160
 polymers
161
 and small molecules.
162,163
  
The second type of research generally performed using TWIMS uses the additional 
separation capability provided by the mobility dimension for the analysis of mixtures of 
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ions. These include the separation of isomers
164,165
 unachievable on the basis of mass to 
charge alone. Other examples employ TWIMS to improve the resolution obtainable for 
protein conformational states,
166,167
 protein and peptide profiling,
168,169
 
oligonucleotides
170
 and carbohydrate glycomics.
171–174
 Additional separations can also be 
achieved in TWIMS by altering the neutral buffer gas employed for CCS 
measurements
151
 and for enhancing separation when compared to the standard drift gases 
of helium and nitrogen, to more polarisable drift gases such as CO2
175 
and binary gas 
mixtures.
176
    
  57 
 References 
1. J. K. Fawcett and J. E. Scott, Journal of Clinical Pathology, 1960, 13, 156–159. 
2. M. Dubois, K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith, Analytical 
Chemistry, 1956, 28, 350–356. 
3. O. Folin and J. Morris, Journal of Biological Chemistry, 1914, 17, 469–473. 
4. R. S. Yalow and S. A. Berson, Nature, 1959, 184, 1648–1649. 
5. A. H. B. Wu, Clinica Chimica Acta; International Journal of Clinical Chemistry, 
2006, 369, 119–124. 
6. G. Kohler and C. Milstein, Nature, 1975, 256, 495–497. 
7. A. Patel and A. K. Campbell, Clinical Chemistry, 1983, 29, 1604–1608. 
8. R. M. Lequin, Clinical Chemistry, 2005, 51, 2415–2418. 
9. E. Bertol, F. Vaiano, S. Furlanetto, and F. Mari, Journal of Pharmaceutical and 
Biomedical Analysis, 2013, 84, 168–172. 
10. L. J. Kricka and C. Chemistry, Clinical Chemistry, 2000, 46, 1037–1038. 
11. H. Krone and H. D. Beckey, Organic Mass Spectrometry, 1969, 2, 427–429. 
12. H. R. Morris, M. Panico, M. Barber, R. S. Bordoli, R. D. Sedgwick, and A. Tyler, 
Biochemical and Biophysical Research Communications, 1981, 101, 623–631. 
13. J. Fenn, M. Mann, and C. Meng, Science, 1989, 246, 64–71. 
14. M. Karas, D. Bachmann, and F. Hillenkamp, Analytical Chemistry, 1985, 57, 
2935–2939.  
15. A. H. B. Wu and D. French, Clinica Chimica Acta; International Journal of 
Clinical Chemistry, 2013, 420, 4–10. 
16. P.O. Hétu, R. Robitaille, and B. Vinet, Journal of Chromatography. B, Analytical 
Technologies in the Biomedical and Life Sciences, 2012, 883-884, 95–101. 
17. L. D. Bowers, Clinical Chemistry, 1997, 43, 1299–1304. 
18. Y. Lee, K. K. Y. Lai, and S. M. H. Sadrzadeh, Clinical Biochemistry, 2013, 46, 
1118–1124. 
  58 
19. C. E. Yesalis and M. S. Bahrke, International Sports Studies, 2002, 24, 42–76. 
20. M. Thevis, T. Piper, S. Beuck, H. Geyer, and W. Schänzer, Rapid Communications 
in Mass Spectrometry, 2013, 27, 1173–1182. 
21. Y. Al-Saffar, N. N. Stephanson, and O. Beck, Journal of Chromatography. B, 
Analytical Technologies in the Biomedical and Life Sciences, 2013, 930, 112–120. 
22. S. Laks, A. Pelander, E. Vuori, E. Ali-Tolppa, E. Sippola, I. Ojanpera, and I. 
Ojanperä, Analytical Chemistry, 2004, 76, 7375–7379. 
23. N. Zhu, D. LeGatt, and A. Turner, Annals of Internal Medicine, 2009, 150, 287–
289. 
24. A. H. Wu, R. Gerona, P. Armenian, D. French, M. Petrie, and K. L. Lynch, 
Clinical Toxicology (Philadelphia, Pa.), 2012, 50, 733–742. 
25. H. W. Vesper and J. C. Botelho, The Journal of Steroid Biochemistry and 
Molecular Biology, 2010, 121, 513–519. 
26. K. W. Phinney, M. Bedner, S. S.-C. Tai, V. V Vamathevan, L. C. Sander, K. E. 
Sharpless, S. A. Wise, J. H. Yen, R. L. Schleicher, M. Chaudhary-Webb, C. M. 
Pfeiffer, U. States, J. M. Betz, P. M. Coates, and M. F. Picciano, Analytical 
Chemistry, 2012, 84, 956–962. 
27. T. Fiers, B. Casetta, B. Bernaert, E. Vandersypt, M. Debock, and J.-M. Kaufman, 
Journal of Chromatography. B, Analytical Technologies in the Biomedical and 
Life Sciences, 2012, 893-894, 57–62. 
28. N. Kahric-Janicic, S. J. Soldin, O. P. Soldin, T. West, J. Gu, and J. Jonklaas, 
Thyroid: Official Journal of the American Thyroid Association, 2007, 17, 303–
311. 
29. P. Roose and U. A. T. Brinkman, TrAC Trends in Analytical Chemistry, 2005, 24, 
897–926. 
30. M. M. Kushnir, T. Blamires, A. L. Rockwood, W. L. Roberts, B. Yue, E. Erdogan, 
A. M. Bunker, and A. W. Meikle, Clinical Chemistry, 2010, 56, 1138–1147. 
31. A. C. Heijboer, M. A. Blankenstein, I. P. Kema, and M. M. Buijs, Clinical 
Chemistry, 2012, 58, 543–548. 
32. W. M. Pardridge and L. J. Mietus, The Journal of Clinical Investigation, 1979, 64, 
145–154. 
  59 
33. H. E. van Deventer, D. R. Mendu, A. T. Remaley, and S. J. Soldin, Clinical 
Chemistry, 2011, 57, 122–127. 
34. R. L. Weiss, American Journal of Clinical Pathology, 2012, 138, 20–6. 
35. D. J. Weston, Analyst, 2010, 135, 661–668. 
36. Z. Takats, J. M. Wiseman, B. Gologan, R. G. Cooks, and Z. Takáts, Science (New 
York, N.Y.), 2004, 306, 471–473. 
37. R. B. Cody, J. A. Laramée, and H. D. Durst, Analytical Chemistry, 2005, 77, 
2297–2302. 
38. M.-Z. Huang, S.-C. Cheng, Y.-T. Cho, and J. Shiea, Analytica Chimica Acta, 
2011, 702, 1–15. 
39. D. J. Weston, R. Bateman, I. D. Wilson, T. R. Wood, and C. S. Creaser, Analytical 
Chemistry, 2005, 77, 7572–7580. 
40. I. Cotte-Rodriguez and H. Hernandez-Soto, Analytical Chemistry, 2008, 80, 1512–
1519. 
41. S. E. Edison, L. A. Lin, and L. Parrales, Food Additives & Contaminants. Part A, 
Chemistry, Analysis, Control, Exposure & Risk Assessment, 2011, 28, 1393–1404. 
42. M. Li, H. Chen, X. Yang, J. Chen, and C. Li, Atmospheric Environment, 2009, 43, 
2717–2720. 
43. S. J. Valentine, M. D. Plasencia, X. Liu, M. Krishnan, S. Naylor, H. R. Udseth, R. 
D. Smith, and D. E. Clemmer, Journal of Proteome Research, 2006, 5, 2977–
2984. 
44. H. Chen, Z. Pan, and N. Talaty, Rapid Communications in Mass Spectrometry, 
2006, 20, 1577–1584. 
45. C. Petucci and J. Diffendal, Journal of Mass Spectrometry, 2008, 43, 1565–1568. 
46. D. I. Carroll, I. N. Stillwell, K. D. Haegele, E. C. Horning, I. Dzidic, and R. N. 
Stillwell, Analytical Chemistry, 1975, 47, 2369–2373. 
47. C. N. McEwen and B. S. Larsen, Journal of the American Society for Mass 
Spectrometry, 2009, 20, 1518–1521. 
48. P. B. Fayad, M. Prévost, and S. Sauvé, Analytical Chemistry, 2010, 82, 639–645. 
  60 
49. L. V Ratcliffe, F. J. M. Rutten, D. A. Barrett, T. Whitmore, D. Seymour, C. 
Greenwood, Y. Aranda-Gonzalvo, S. Robinson, and M. McCoustra, Analytical 
Chemistry, 2007, 79, 6094–6101. 
50. M. Dole, The Journal of Chemical Physics, 1968, 49, 2240. 
51. J. A. Loo, Mass Spectrometry Reviews, 1997, 16, 1–23. 
52. V. Reinhold, B. Reinhold, and S. Chan, Methods in Enzymology, Elsevier, 1996, 
vol. 271, pp. 377–402. 
53. R. Saf, C. Mirtl, and K. Hummel, Acta Polymerica, 1997, 48, 513–526. 
54. E. de Hoffman and V. Stroobant, Mass Spectrometry; Princibles and Applications, 
Jonh Wiley & Sons Ltd, Chichester, 3rd ed., 2007. 
55. T. T. C. Rohner, N. Lion, H. H. H. Girault, and E. Physique, Physical Chemistry 
Chemical Physics, 2004, 6, 3056–3068. 
56. R. L. Grimm and J. L. Beauchamp, The Journal of Physical Chemistry. A, 2010, 
114, 1411–1419. 
57. P. Kebarle and M. Peschke, Analytica Chimica Acta, 2000, 406, 11–35. 
58. J. V. Iribarne, The Journal of Chemical Physics, 1976, 64, 2287. 
59. T. Dulcks and R. Juraschek, Journal of Aerosol Science, 1999, 30, 927–943. 
60. T. M. Annesley, Clinical Chemistry, 2003, 49, 1041–1044. 
61. H. Chen, A. Venter, and R. G. Cooks, Chemical Communications, 2006, 2042–
2044. 
62. W. S. Law, R. Wang, B. Hu, C. Berchtold, L. Meier, H. Chen, and R. Zenobi, 
Analytical Chemistry, 2010, 82, 4494–4500. 
63. H. Chen, S. Yang, A. Wortmann, and R. Zenobi, Angewandte Chemie 
(International ed. in English), 2007, 46, 7591–7594. 
64. B. Hu, X. Zhang, M. Li, X. Peng, J. Han, S. Yang, Y. Ouyang, and H. Chen, 
Analyst, 2011, 136, 4977–4985. 
65. X. Li, X. Fang, Z. Yu, G. Sheng, M. Wu, J. Fu, F. Yan, and H. Chen, Analytical 
Methods, 2012, 4, 1212-1217. 
  61 
66. L. Meier, C. Berchtold, S. Schmid, and R. Zenobi, Analytical Chemistry, 2012, 84, 
2076–2080. 
67. A. Venter, P. E. Sojka, and R. G. Cooks, Analytical Chemistry, 2006, 78, 8549–
8555. 
68. C. Wu, W. F. Siems, and H. H. Hill, Analytical Chemistry, 2000, 72, 396–403. 
69. D.-Y. Chang, C.-C. Lee, and J. Shiea, Analytical Chemistry, 2002, 74, 2465–2469. 
70. L. Meier, S. Schmid, C. Berchtold, and R. Zenobi, European Journal of Mass 
Spectrometry, 2011, 17, 345–351. 
71. M. Orme and A. Engineering, Progress in Energy and Combustion Science, 1997, 
23, 65–79. 
72. R. Wang, A. J. Gröhn, L. Zhu, R. Dietiker, K. Wegner, D. Günther, and R. Zenobi, 
Analytical and Bioanalytical Chemistry, 2012, 402, 2633–2643. 
73. B. Hu, S. Yang, M. Li, H. Gu, and H. Chen, Analyst, 2011, 136, 3599–3601. 
74. X. Zhang, Y. Liu, J. Zhang, Z. Hu, B. Hu, L. Ding, L. Jia, and H. Chen, Talanta, 
2011, 85, 1665–1671. 
75. N. Xu, Z.-Q. Zhu, S.-P. Yang, J. Wang, H.-W. Gu, Z. Zhou, and H.-W. Chen, 
Chinese Journal of Analytical Chemistry, 2013, 41, 523–528. 
76. Z. Zhou, M. Jin, J. Ding, Y. Zhou, J. Zheng, and H. Chen, Metabolomics, 2007, 3, 
101–104. 
77. H. Gu, H. Chen, Z. Pan, A. U. Jackson, N. Talaty, B. Xi, C. Kissinger, C. Duda, D. 
Mann, D. Raftery, and R. G. Cooks, Analytical Chemistry, 2007, 79, 89–97. 
78. A. U. Jackson, S. R. Werner, N. Talaty, Y. Song, K. Campbell, R. G. Cooks, and J. 
A. Morgan, Analytical Biochemistry, 2008, 375, 272–281. 
79. X. Li, X. Fang, Z. Yu, G. Sheng, M. Wu, J. Fu, and H. Chen, Analytica Chimica 
Acta, 2012, 748, 53–57. 
80. L. Zhu, Z. Hu, G. Gamez, W. S. Law, H. Chen, S. Yang, K. Chingin, R. M. 
Balabin, R. Wang, T. Zhang, and R. Zenobi, Analytical and Bioanalytical 
Chemistry, 2010, 398, 405–413. 
81. W. S. Law, H. W. Chen, R. Balabin, C. Berchtold, L. Meier, and R. Zenobi, 
Analyst, 2010, 135, 773–778. 
  62 
82. L. Zhu, G. Gamez, H. Chen, K. Chingin, R. Zenobi, and C.- Zu, Chemical 
Communications (Cambridge, England), 2009, 81, 123–129. 
83. J.-Q. Li, Y.-F. Zhou, J.-H. Ding, S.-P. Yang, and H.-W. Chen, Chinese Journal of 
Analytical Chemistry, 2008, 36, 1300–1304. 
84. C. Liu, X. Zhang, S. Xiao, B. Jia, S. Cui, J. Shi, N. Xu, X. Xie, H. Gu, and H. 
Chen, Talanta, 2012, 98, 79–85. 
85. B. J. McCullough, T. Bristow, G. O’Connor, and C. Hopley, Rapid 
Communications in Mass Spectrometry: RCM, 2011, 25, 1445–1451. 
86. P. J. Gallimore and M. Kalberer, Environmental Science & Technology, 2013, 47, 
7324–7331. 
87. L. A. Doezema, T. Longin, W. Cody, V. Perraud, M. L. Dawson, M. J. Ezell, J. 
Greaves, K. R. Johnson, and B. J. Finlayson-Pitts, RSC Advances, 2012, 2, 2930-
2938. 
88. H. Gu, B. Hu, J. Li, S. Yang, J. Han, and H. Chen, Analyst, 2010, 135, 1259–1267. 
89. J. C. Reynolds, G. J. Blackburn, V. H. Moll, M. D. Howdle, E. L. Harry, L. J. 
Brown, C. S. Creaser, C. L. P. Thomas, C. Guallar-Hoyas, V. Bocos-Bintintan, and 
G. Kaur-Atwal, Analytical Chemistry, 2010, 82, 2139–2144. 
90. H. Chen, A. Wortmann, W. Zhang, and R. Zenobi, Angewandte Chemie 
(International ed. in English), 2007, 46, 580–593. 
91. J. Ding, S. Yang, D. Liang, H. Chen, Z. Wu, L. Zhang, and Y. Ren, Analyst, 2009, 
134, 2040–2050. 
92. G. Gamez, L. Zhu, A. Disko, H. Chen, V. Azov, K. Chingin, G. Kramer, R. 
Zenobi, and G. Krämer, Chemical Communications, 2011, 47, 1–4. 
93. C. Berchtold, L. Meier, and R. Zenobi, International Journal of Mass 
Spectrometry, 2011, 299, 145–150. 
94. K. Chingin, G. Gamez, H. Chen, L. Zhu, and R. Zenobi, Rapid Communications in 
Mass Spectrometry: RCM, 2008, 22, 2009–2014. 
95. K. Chingin, H. Chen, and G. Gamez, Analytical Chemistry, 2008, 81, 123–129. 
96. J. Ding, H. Gu, S. Yang, M. Li, J. Li, and H. Chen, Analytical Chemistry, 2009, 
81, 8632–8638. 
  63 
97. Y. Liu, X. Zhang, Y. Ouyang, Z. Hu, L. Ma, J. Zhang, J. Lin, and H. Chen, 
Journal of Mass Spectrometry: JMS, 2011, 46, 794–803. 
98. W. S. Law, H. Chen, J. Ding, S. Yang, L. Zhu, G. Gamez, K. Chingin, Y. Ren, and 
R. Zenobi, Angewandte Chemie (International ed. in English), 2009, 48, 8277–
8280. 
99. X. Zhang, N. Wang, Y. Zhou, Y. Liu, J. Zhang, and H. Chen, Analytical Methods, 
2013, 5, 311-315. 
100. H. Chen, Y. Sun, A. Wortmann, H. Gu, and R. Zenobi, Analytical Biochemistry, 
2007, 79, 1447–1455. 
101. Z. Wu, K. Chingin, H. Chen, L. Zhu, B. Jia, and R. Zenobi, Analytical and 
Bioanalytical Chemistry, 2010, 397, 1549–1556. 
102. H. Chen, B. Hu, Y. Hu, Y. Huan, Z. Zhou, and X. Qiao, Journal of the American 
Society for Mass Spectrometry, 2009, 20, 719–722. 
103. H. Gu, S. Yang, J. Li, B. Hu, H. Chen, L. Zhang, and Q. Fei, Analyst, 2010, 135, 
779-788. 
104. J. P. Williams and J. H. Scrivens, Rapid Communications in Mass Spectrometry, 
2008, 187–196. 
105. F. Basile, S. Zhang, Y.-S. Shin, and B. Drolet, Analyst, 2010, 135, 797–803. 
106. N. Spooner, Bioanalysis, 2010, 2, 1781. 
107. J. M. Wiseman, C. A. Evans, C. L. Bowen, and J. H. Kennedy, Analyst, 2010, 135, 
720-725. 
108. N. E. Manicke, Q. Yang, H. Wang, S. Oradu, Z. Ouyang, and R. G. Cooks, 
International Journal of Mass Spectrometry, 2011, 300, 123–129. 
109. G. Corso, O. D’Apolito, D. Garofalo, G. Paglia, and A. Dello Russo, Biochimica et 
Biophysica Acta, 2011, 1811, 669–679. 
110. M. Zhou, J. F. McDonald, and F. M. Fernández, Journal of the American Society 
for Mass Spectrometry, 2010, 21, 68–75. 
111. A. L. Dill, L. S. Eberlin, A. B. Costa, C. Zheng, D. R. Ifa, L. Cheng, T. A. 
Masterson, M. O. Koch, O. Vitek, and R. G. Cooks, Chemistry (Weinheim an der 
Bergstrasse, Germany), 2011, 17, 2897–902.  
  64 
112. A. L. Dill, L. S. Eberlin, C. Zheng, A. B. Costa, D. R. Ifa, L. Cheng, T. A. 
Masterson, M. O. Koch, O. Vitek, and R. G. Cooks, Analytical and Bioanalytical 
Chemistry, 2010, 398, 2969–2978. 
113. Z. Takáts, J. M. Wiseman, R. G. Cooks, and Z. Takats, Journal of Mass 
Spectrometry: JMS, 2005, 40, 1261–1275. 
114. J. Balog, L. Sasi-Szabó, J. Kinross, M. R. Lewis, L. J. Muirhead, K. Veselkov, R. 
Mirnezami, B. Dezső, L. Damjanovich, A. Darzi, J. K. Nicholson, and Z. Takáts, 
Science translational medicine, 2013, 5, 194. 
115. D. L. Poster, M. M. Schantz, L. C. Sander, and S. A. Wise, Analytical and 
Bioanalytical Chemistry, 2006, 386, 859–881. 
116. J. C. Chow, J. Z. Yu, J. G. Watson, S. S. H. Ho, T. L. Bohannan, M. D. Hays, and 
K. K. Fung, Journal of Environmental Science and Health. Part A, 
Toxic/Hazardous Substances & Environmental Engineering, 2007, 42, 1521–1541. 
117. A. S. Tsibart and A. N. Gennadiev, Eurasian Soil Science, 2013, 46, 728–741. 
118. E. Baltussen, P. Sandra, F. David, and C. Cramers, Journal of Microcolumn 
Separations, 1999, 11, 737–747. 
119. B. Tienpont, F. David, K. Desmet, and P. Sandra, Analytical and Bioanalytical 
Chemistry, 2002, 373, 46–55. 
120. M. Kawaguchi, N. Sakui, N. Okanouchi, R. Ito, K. Saito, S. Izumi, T. Makino, and 
H. Nakazawa, Journal of Chromatography. B, Analytical Technologies in the 
Biomedical and Life Sciences, 2005, 820, 49–57. 
121. A. Stopforth, C. J. Grobbelaar, A. M. Crouch, and P. Sandra, Journal of 
Separation Science, 2007, 30, 257–265. 
122. N. Fucci, N. De Giovanni, and M. Chiarotti, Forensic Science International, 2003, 
134, 40–45. 
123. R. B. Wilson, J. C. Hoggard, and R. E. Synovec, Analytical Chemistry, 2012, 84, 
4167–4173. 
124. J. Wu, C. S. Hughes, P. Picard, S. Letarte, M. Gaudreault, J.-F. Lévesque, D. A. 
Nicoll-Griffith, and K. P. Bateman, Analytical Chemistry, 2007, 79, 4657–4665. 
125. J. G. Swales, R. T. Gallagher, M. Denn, and R. M. Peter, Journal of 
Pharmaceutical and Biomedical Analysis, 2011, 55, 544–551. 
  65 
126. J. J. Thomson, Rays of Positive Electricity and Their Application to Chemical 
Analysis, Longmans Green and Co, 1913.  
127. F. W. Aston, Science, 1933, 78, 5–6. 
128. J. De Laeter, M. D. M. Kurz, and J. De Laeter, Journal of Mass Spectrometry, 
2006, 41, 847–854. 
129. A. Dempster, Physical Review, 1918, 11, 316–325. 
130. W. Paul, Reviews of Modern Physics, 1990, 62, 531–540. 
131. W. E. Stephens, Bulletin of the American Physical Society, 1946, 21, 22. 
132. A. G. Marshall, C. L. Hendrickson, and G. S. Jackson, Mass Spectrometry 
Reviews, 1998, 17, 1–35. 
133. A. Makarov, Analytical Chemistry, 2000, 72, 1156–1162. 
134. W. C. Wiley and I. H. McLaren, Review of Scientific Instruments, 1955, 26, 1150-
1157.  
135. B. A. Mamyrin, V. I. Karataev, D. V Shmikk, and V. A. Zagulin, Zh. Eksp. Teor. 
Fiz, 1973, 37, 45–48. 
136. Y. Chen, M. Gonin, K. Fuhrer, a Dodonov, C. Su, and H. Wollnik, International 
Journal of Mass Spectrometry, 1999, 185-187, 221–226. 
137. J.-L. H. Jiwan, P. Wallemacq, and M.-F. Hérent, Clinical Biochemistry, 2011, 44, 
136–147. 
138. K. Kingdon, Physical Review, 1923, 21, 408–418. 
139. V. D. Berkout, R. J. Cotter, and D. P. Segers, Journal of the American Society for 
Mass Spectrometry, 2001, 12, 641–647. 
140. A. J. P. Martin, Annual Review of Biochemistry, 1950, 19, 517–542. 
141. G. A. Eiceman, Trends in Analytical Chemistry, 2002, 21, 259–275.  
142. G. Eiceman and Z. Karpas, Ion Mobility Spectrometry, CRC Press, 1994. 
143. E. Mason and H. Schamp, Annals of Physics, 1958, 4, 233–270. 
144. E. A. Mason and E. W. McDaniel, Transport Properties of Ions in Gases, Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim, FRG, 1988. 
  66 
145. C. S. Creaser, J. R. Griffiths, C. J. Bramwell, S. Noreen, A. Hill, C. L. P. Thomas, 
and C. A. Hill, Analyst, 2004, 129, 984-994.  
146. S. Guan and A. G. Marshall, Journal of the American Society for Mass 
Spectrometry, 1996, 7, 101–106. 
147. K. Giles, S. D. Pringle, K. R. Worthington, D. Little, J. L. Wildgoose, and R. H. 
Bateman, Rapid Communications in Mass Spectrometry, 2004, 18, 2401–2414. 
148. S. A. S. Shaffer, K. Tang, G. A. Anderson, D. C. Prior, H. R. Udseth, and R. D. 
Smith, Rapid Communications in Mass Spectrometry, 1997, 11, 1813–1817. 
149. S. D. Pringle, K. Giles, J. L. Wildgoose, J. P. Williams, S. E. Slade, K. 
Thalassinos, R. H. Bateman, M. T. Bowers, and J. H. Scrivens, International 
Journal of Mass Spectrometry, 2007, 261, 1–12. 
150. V. E. Wright, F. Castro-Gómez, E. Jurneczko, J. C. Reynolds, A. Poulton, S. D. R. 
Christie, P. Barran, C. Bo, and C. S. Creaser, International Journal for Ion 
Mobility Spectrometry, 2013, 16, 61–67. 
151. M. M. F. Bush, I. D. G. I. Campuzano, and C. V. Robinson, Analytical Chemistry, 
2012, 84, 7124–7130. 
152. R. Chawner, B. Mccullough, K. Giles, P. E. Barran, S. J. Gaskell, and C. E. Eyers, 
Journal of Proteome Research, 2012, 11, 5564–5572. 
153. M. F. Bush, Z. Hall, K. Giles, J. Hoyes, C. V Robinson, and B. T. Ruotolo, 
Analytical Chemistry, 2010, 82, 9557–9565. 
154. L. S. Fenn and J. A. McLean, Physical Chemistry Chemical Physics, 2011, 13, 
2196–205. 
155. A. Moradian, M. Scalf, M. S. Westphall, L. M. Smith, and D. J. Douglas, 
International Journal of Mass Spectrometry, 2002, 219, 161–170. 
156. G. J. Dear, J. Munoz-Muriedas, C. Beaumont, A. Roberts, J. Kirk, J. P. Williams, 
and I. Campuzano, Rapid Communications in Mass Spectrometry, 2010, 24, 3157–
3162. 
157. E. L. Harry, D. J. Weston, A. W. T. Bristow, I. D. Wilson, and C. S. Creaser, 
Journal of Chromatography. B, Analytical Technologies in the Biomedical and 
Life Sciences, 2008, 871, 357–361. 
158. K. Pagel and D. J. Harvey, Analytical Chemistry, 2013, 85, 5138–5145. 
  67 
159. J. P. Williams, J. A. Lough, I. Campuzano, K. Richardson, and P. J. Sadler, Rapid 
Communications in Mass Spectrometry, 2009, 23, 3563–3569. 
160. W. B. Ridenour, M. Kliman, J. A. McLean, and R. M. Caprioli, Analytical 
Chemistry, 2010, 82, 1881–1889. 
161. C. A. Scarff, J. R. Snelling, M. M. Knust, C. L. Wilkins, and J. H. Scrivens, 
Journal of the American Chemical Society, 2012, 134, 9193–9198. 
162. I. Campuzano, M. F. Bush, C. V. Robinson, C. Beaumont, K. Richardson, and H. 
I. H. Kim, Analytical Chemistry, 2012, 84, 1026–1033. 
163. T. W. Knapman, J. T. Berryman, I. Campuzano, S. A. Harris, and A. E. Ashcroft, 
International Journal of Mass Spectrometry, 2010, 298, 17–23. 
164. J. J. Santos, S. H. Toma, P. M. Lalli, M. F. Riccio, M. N. Eberlin, H. E. Toma, and 
K. Araki, Analyst, 2012, 137, 4045–4051. 
165. L. Ahonen, M. Fasciotti, G. B. A. G. Gennäs, T. Kotiaho, R. J. Daroda, M. 
Eberlin, and R. Kostiainen, Journal of Chromatography. A, 2013, 1310, 133–137. 
166. C. A. Scarff, A. Sicorello, R. J. L. Tomé, S. Macedo-Ribeiro, A. E. Ashcroft, and 
S. E. Radford, International Journal of Mass Spectrometry, 2013, 345, 63–70. 
167. W. Kaaki, M. Woudstra, B. Gontero, and F. Halgand, Rapid Communications in 
Mass Spectrometry, 2013, 27, 179–186. 
168. P. V. P. Shliaha, N. J. N. Bond, L. Gatto, and K. S. Lilley, Journal of Proteome 
Research, 2013, 12, 2323–2339. 
169. S. R. Harvey, C. E. Macphee, and P. E. Barran, Methods (San Diego, Calif.), 2011, 
54, 454–461. 
170. K. C. Porter and J. L. Beck, International Journal of Mass Spectrometry, 2011, 
304, 195–203. 
171. D. J. Harvey, C. A. Scarff, M. Edgeworth, M. Crispin, C. N. Scanlan, F. Sobott, S. 
Allman, K. Baruah, L. Pritchard, and J. H. Scrivens, Electrophoresis, 2013, 34, 
2368–2378. 
172. H. Li, B. Bendiak, W. F. Siems, D. R. Gang, and H. H. Hill, Analytical Chemistry, 
2013, 85, 2760–2769. 
173. H. Li, K. Giles, B. Bendiak, K. Kaplan, W. F. Siems, and H. H. Hill, Analytical 
Chemistry, 2012, 84, 3231–3239. 
  68 
174. J. P. Williams, M. Grabenauer, R. J. Holland, C. J. Carpenter, M. R. Wormald, K. 
Giles, D. J. Harvey, R. H. Bateman, J. H. Scrivens, and M. T. Bowers, 
International Journal of Mass Spectrometry, 2010, 298, 119–127. 
175. M. Fasciotti, G. B. Sanvido, V. G. Santos, P. M. Lalli, M. McCullagh, G. F. de Sá, 
R. J. Daroda, M. G. Peter, and M. N. Eberlin, Journal of Mass Spectrometry, 2012, 
47, 1643–1647. 
176. M. D. Howdle, C. Eckers, A. M.-F. Laures, and C. S. Creaser, International 
Journal of Mass Spectrometry, 2010, 298, 72–77.  
  69 
 
 
 
 
CHAPTER TWO 
 
Determination of free desmosine and 
isodesmosine as urinary biomarkers 
of lung disorder using ultra 
performance liquid chromatography-
ion mobility-mass spectrometry 
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2.1. Introduction 
 
Chronic obstructive pulmonary disease (COPD) is defined as a completely irreversible, 
progressive air flow obstruction, associated with lung inflammation caused by prolonged 
exposure to noxious particles and gases, particularly tobacco smoke.
1
 The term COPD 
includes a variety of pathological disorders characterized by acute inflammatory 
processes that present identical symptoms; these include bronchitis, asthma, cystic 
fibrosis, acute lung injury, emphysema and alpha-1-antiprotease deficient patients.
2
 
These inflammatory reactions to exogenous
3
 and genetic factors,
4-6
 initiate the 
recruitment (chemotaxis) of the cells involved in the immune system.
7
 COPD is still 
under-diagnosed with approximately half of severe/very severe patients in the United 
Kingdom having any form of respiratory diagnosis.
8
 
The prognosis of COPD at the severe/very severe stages is poor with, currently, no 
prospect to reverse lung degradation.
9
 The early detection and stratification of COPD 
patients can enable more focused treatment regimes to be employed
9-11 
and a variety of 
biomarker candidates have been tested through multi-centre clinical based trials.
11
 
Biomarkers identified include the elastin degradation product desmosine (DES) and its 
isomer isodesmosine (IDES). DES and IDES are pyridinium ring containing amino acids 
(Figure 2.1) produced by the aggregation of four lysine residues,
12
 which form the highly 
stable cross-links unique to elastin.  
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Figure 2.1. Chemical structures of the elastin cross-linking isomers (a) desmosine 
and (b) isodesmosine, [M]
+
 = 526.2877. 
 
During the lung repair process, DES and IDES molecules are liberated from the 
extracellular matrix (ECM) in the free form (15%) and bound form, associated with 
peptide fragments (85%). Concentrations range from 0.5 – 3 μg/g creatinine and 5 – 14 
μg/g creatinine for free and total DES/IDES, respectively, in healthy subjects,13,14 
normalized to urinary creatinine to adjust for individual variation in sample volume and 
rate of urine production.
15
 The presence of DES/IDES in the human body is independent 
of diet and is elimination route specific to urine.
16
 These factors make DES and IDES 
potentially important biomarkers for detection and monitoring of COPD.
17-20
 
The analytical determination of DES/IDES has been previously reviewed by Viglio et al. 
21
 with reported methods including amino-acid analysis, radio-immunoassay (RIA) and 
enzyme-linked immunosorbant assays (ELISA). These methods were of limited clinical 
practicality due to extensive sample preparation required and false positives resulting 
from cross-reactivity.
19
 The majority of recent studies for the detection and quantitation 
of DES/IDES, have employed high performance liquid chromatography-mass 
N
+
NH2
O OH
NH2
O
OH
NH2
O
OH
NH2
O
OH
N
+
NH2
O
OH
NH2
OH
O
NH2
O OH
NH2
O OH
a) b) 
  72 
spectrometry (LC-MS)
13,14, 22-25
 with ion-pairing for the separation of DES/IDES on ODS 
based stationary phases, due to the cationic nature of these analytes.  
Ma et al.
13,14
 applied LC-MS and LC-MS/MS to the separation of DES/IDES in healthy 
urine, with a partial separation of DES/IDES peaks achieved in 35 minute LC run. The 
LDR of their method (0.1 – 50 ng on column; based on standards), indicated the potential 
of applying an ion pairing liquid chromatography approach to the quantification of free 
DES/IDES in urine. Recently, Albarbarawi et al.
24
 reported the LC-MS/MS analysis of 
total (free and bound) DES/IDES to predict the extent of lung damage based upon the 
combined DES/IDES response, but without chromatographic separation of the isomers. 
An ultra high performance liquid chromatography (UHPLC) approach has been reported 
by Shiraishi et al.
25
 with a chromatographic run time of 15 minutes for the determination 
of total DES/IDES after bound DES/IDES was released by acid hydrolysis. These studies 
reported DES/IDES levels to increase (approximately 100%) in COPD affected 
individuals, relative to healthy patients. However, the liberation of free DES/IDES from 
associated peptide fragments requires a lengthy acid hydrolysis procedure, typically 
taking over 24-48 hours. 
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2.2. Aims and Objectives 
 
 The generation of a rapid ion-pairing UHPLC method for the resolution of the 
DES and IDES urinary metabolites that are associated with the COPD lung 
disorder.  
 
 The targeted detection of the free unbound fraction of DES and IDES from the 
urine biofluid. 
 
 Investigate the application of an ion mobility separation for a) the separation of 
the two isomers and b) the enhancement of the MS data. 
 
 Determine the levels of DES and IDES in the urine of COPD sufferers for 
comparison against healthy individuals.    
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2.3. Experimental 
 
2.3.1. Chemicals 
 
Elastin soluble DES, IDES and deuterated IDES-d9 were provided by AstraZeneca R&D 
(Charnwood, Loughborough, UK). Acetonitrile (analytical grade), methanol (analytical 
grade), water (analytical grade), ammonium formate (>99.9%) and sodium acetate 
(analytical grade) were purchased from Fisher Scientific (Loughborough, UK). 
Heptafluorobutyric acid, HFBA, (>99%) was purchased from Acros Organics (Geel, 
Belgium). HPLC grade formic acid (>99.9%) and creatinine (>99%) was purchased from 
Sigma-Aldrich (Gillingham, UK). 
 
2.3.2. Preparation of DES, IDES and IDES-d9 standards 
 
Standards of DES and IDES with concentrations 10, 25, 50, 100, 200, 300, 400 and 500 
ng/mL were prepared, each containing 25 ng/mL of IDES-d9. All solutions were freshly 
prepared in 85:15 H2O : H2O:MeOH (60:40) (v/v) containing 5 mmol/L ammonium 
formate, 0.1% (v/v) HFBA and pH buffered to 2.5 using formic acid. 
 
2.3.3. UHPLC chromatographic conditions 
 
The chromatographic separations were performed using a Waters AQUITY UHPLC 
(Waters, Manchester, UK). DES/IDES separation was achieved on an AQUITY BEH 
C18 column (2.1 x 100 mm, 1.7 μm Waters, Manchester, UK) under isocratic conditions 
with a flow rate of 600 μL/min and an injection volume of 20μL. Mobile phase A 
consisted of 5 mmol/L ammonium formate in H2O with 0.1% (v/v) HFBA. Mobile phase 
B consisted of 5 mmol/L ammonium formate in 60:40 H2O: MeOH with 0.1% (v/v) 
HFBA, each buffered to a pH of 2.5 using formic acid. A 5 minute isocratic flow of 85:15 
mobile phase A: mobile phase B was used to elute DES and IDES. The mobile phase 
composition was then raised to 100% of mobile phase B for 0.5 min before returning to 
the starting conditions. The total run time was 6 minutes. 
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2.3.4. IM-MS conditions 
 
IM-MS analyses were undertaken using a Waters Synapt HDMS spectrometer (Waters, 
Manchester, UK) using an ESI source operated in positive ionization mode with 
enhanced duty cycle (EDC) set at m/z 526 to transmit the DES/IDES and IDES-d9 ions. 
The source and desolvation temperatures were set to 150°C and 450°C, gas flow (N2) 
rates were set to 50 L/h and 1000 L/h respectively. The tri-wave drift cell conditions were 
set at 20 mL/min drift gas (N2) with a travelling wave height/velocity of 5 V and 300 m/s. 
IM-MS allowed nested mass spectra (0.065 ms/scan) and ion mobility spectra (13 
ms/scan) to be acquired within the timescale of a typical UPLC peak, width a 2 s full with 
at half maximum (FWHM). The acquired UPLC-IM-MS data was processed using 
DriftScope and MassLynx 4.1 (Waters, Manchester, UK). 
 
2.3.5. Urine sample preparation 
 
Urine samples obtained from healthy volunteers and COPD patients were provided by 
AstraZeneca R&D Charnwood. To 1 mL of a combined (male and female) urine sample, 
80 μL of a 3.8 nmol/mL IDES-d9 solution and 120 μL of 10% HFBA solution were added. 
The solution was then subjected to SPE clean-up on an Oasis HLB 30 mg cartridge 
(Waters, Manchester, UK). The cartridge was conditioned with 1 mL of acetonitrile 
(ACN) containing 1% (v/v) HFBA and then equilibrated using 1 mL of aqueous 1% (v/v) 
HFBA. Urine samples (1.2 mL) were loaded onto the Oasis HLB solid phase, the column 
was washed with 1 mL of aqueous 1% (v/v) HFBA and eluted with 1 mL of 1% (v/v) 
HFBA in ACN. The extracts were then frozen (-80 °C) until required. 
Prior to analysis, the urine extracts were thawed, evaporated to dryness using a TurboVap 
LV system (Biotarge AB, Uppsala Sweden) and reconstituted in 30 μL of freshly 
prepared H2O:MeOH (94:6, v/v) containing 0.1% (v/v) HFBA ion pairing reagent, 
buffered to pH 2.5 using formic acid and ammonium formate. 
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2.3.6. Creatinine determination 
 
The creatinine concentration in pooled urine samples was determined using an Agilent 
1200 HPLC system with isocratic mobile phase (80:20 (v/v) H2O:MeOH and 10 mmol/L 
sodium acetate) flowing at 1.8 mL/min through a SCX HYPERSIL column (4.6 x 100 
mm, 5 μm, Capital HPLC Ltd). UV detection was carried out (230 nm) with a total run 
time of 2 minutes. Urine samples were diluted (1:4, v/v) with 80:20 (v/v) (H2O:MeOH) 
mobile phase prior to injection (5 μL). Urinary creatinine concentrations were calculated 
based on a calibration curve (R
2
 = 0.99) of known creatinine standards, prepared at 
concentrations of 0.1, 0.5, 1, 2, 3 and 5 mmol/L. 
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2.4. Results and Discussion 
 
2.4.1. UHPLC-IM-MS analysis of DES/IDES standards 
 
The rapid UHPLC chromatographic analysis of DES/IDES was achieved using isocratic 
elution with methanol/water containing HFBA ion pairing reagent, buffered using formic 
acid/ammonium formate (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. UHPLC-IM-MS separation of DES/IDES standards (Rs = 1.9) (a) 
selected ion chromatograms for DES, IDES, m/z 526.29 ± 0.05 (300 ng/mL), and 
IDES-d9, m/z 535.34 ± 0.05, (25 ng/mL). (b) Mobility vs m/z profile for DES and 
IDES (TOF scans/bins 1-200). 
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The separation of DES/IDES was achieved with a total chromatographic run time of 6 
minutes, compared to a 15 minute run time previously reported
25
 which is more suitable 
for high-throughput screening.
24,25
 Optimization of the mobile phase combined with the 
UHPLC (5 µm) stationary phase enabled baseline resolution (Rs = 1.9) of the DES/IDES 
isomers with good inter-day retention time reproducibility (%RSD) of 2.6% and 3.1% 
respectively. The DES/IDES ion drift time vs. retention time profile is shown in Figure 
2b. The mobility range for DES (TOF scans/bins 96-126, td 6.24-8.19 ms) was higher 
than that of IDES (TOF scans/bins 89-121, td 5.78-7.86 ms), indicating small differences 
in the rotationally averaged cross-sections, but the DES/IDES isomers were not resolved 
by ion mobility drift time. The drift time (bin) window selected for the maximum 
response of both DES and IDES isomers was in the range 7.22-7.35 ms, indicated by the 
dotted line in Figure 2b, which provided the best compromise between analytical 
sensitivity and mobility selectivity, and was used in subsequent analyses. Optimized 
UHPLC conditions were tested using a series of DES/IDES standards (10-500 ng/mL), 
each spiked with deuterated IDES-d9 (25 ng/mL) to determine linear dynamic ranges 
(LDR), limit of quantitation (LOQ) and the reproducibility in IM-MS mode. The LDR of 
the UPLC-IM-MS method was determined to be 10-300 ng/mL (r
2
 = 0.99) for DES and 
IDES, respectively (Figure 2.3). 
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Figure 2.3. Quantitative UHPLC-IM-MS response for (a) DES and (b) IDES 
normalized to IDES-d9 internal standard (n=9). 
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The use of IM-MS in quantitative bioanalysis presents a challenge because of the reduced 
dynamic range of the IM technique and the LDR in IM-MS mode is significantly lower 
than in MS mode, because of detector saturation at higher concentrations resulting from 
the pulsed injection of ions into the drift cell. Nevertheless, the LDR is compatible with 
the expected range of concentrations for free DES/IDES in urine from COPD patients 
and healthy controls, making IM-MS suitable for clinical studies. The limit of 
quantitation (10:1 signal/noise ratio) was 0.028 ng/mL and 0.03 ng/mL (0.55 ng and 0.61 
ng on column) for IDES and DES respectively. The LOQ values are equivalent to 0.98 
μg/g creatinine and 1.07 μg/g creatinine for IDES and DES respectively assuming a 
standard creatinine concentration of 5 mmol/L. Sensitivity levels achievable using 
UHPLC-IM-MS allows quantitation of free DES/IDES in urine, removing the 
requirement for the lengthy hydrolysis process (24-48h), used previously for the 
determination of total DES/IDES.
13,14,23,24
 Method reproducibility was determined for a 
DES/IDES concentration in the middle of the LDR (100 ng/mL) over three consecutive 
days giving inter-day % RSDs (n=9) of 3.4% and 3.9% for DES and IDES, respectively, 
comparable with previously reported data.
24
 The comparable precision and improved run 
time of the UHPLC-IM-MS method demonstrates that there is no reduction in analytical 
quality associated with separation of the DES and IDES and doing so allows an 
assessment of DES/IDES variation across subjects. These data demonstrate that the 
linearity, sensitivity and reproducibility of the UHPLC-IM-MS method are satisfactory 
for the quantitation of free DES/IDES in a clinical based setting, in accordance with the 
FDA guidance for industry bioanalytical method validation
31
 and at physiologically 
relevant levels.
13
 
 
2.4.2. High resolution MS/MS measurements 
 
For the analysis of compounds in a mixture many research groups employ MS/MS to 
selectively transmit a particular ion of interest. This method of DES/IDES determination 
has been performed using a variety of low resolution mass analysers such as the 
quadrupole
25
 and triple quadrupole
13,23
 mass spectrometers. These systems provide high 
  81 
sensitivity, but limited mass accuracy (±0.1 Da). The accurate mass measurement of the 
fragmentation products of DES and IDES for elemental composition and calculation of 
parts per million (ppm) errors has been determined. Using an UHPLC-MS/MS based 
approach ions corresponding to the DES/IDES (m/z 526) could be selectively transmitted 
through the quadrupole. The MS/MS data from the separation of DES and IDES is 
provided in Figures 2.4a and 2.4b respectively. 
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Figure 2.4. MS showing the selection and CID fragmentation of a) DES and b) IDES. 
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Using the advantages of a ToF based accurate mass measurement (four decimal places), 
proposes  an alternative fragmentation pattern to that previously described in literature
13
 
based upon the loss of COOH (m/z 44.9977). A COOH mass loss does not agree with the 
accurate mass measurements obtained using the Synapt HDMS system.  
Using the mass differences between the fragments and elemental composition the 
predictive the loss of CONH3 (m/z 45.0215) at fragment peaks 1, 2, 4 and 5 is proposed. 
This loss is predicted by elemental composition and fits the mass differences observed. 
The finding was confirmed using a 0.2 µg/mL IDES sample was created in MeOH and 
tested using an Orbitrap (Thermo Fisher Scientific Exactive) to gain <5 ppm mass error 
for each of the fragments. Using chip based nanoESI (Tri-Versa NanoMate) IDES ions 
were generated and fragmented under CID conditions at 75 eV, the acquired data is 
provided in Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. MS showing the selection and CID fragmentation of IDES using a high 
resolution Orbitrap instrument. 
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Using the Xcaliber software (Thermo Fisher Scientific) each IDES fragment peak was 
annotated with elemental composition and ppm error based upon the loss of CONH3. 
Using this data, ppm errors for the loss of both COOH and CONH3 can be calculated and 
compared as shown in Table 2.1.  
 
Table 2.1. IDES Fragmentation comparing the loss of CONH3 and COOH based 
upon ppm mass error. 
 
 
 
 
 
 
 
 
 
 
 
Based upon observed fragmentation peaks (Orbitrap, Thermo Scientific) and theoretical 
accurate masses (MassLynx, Waters) present compelling evidence for the loss of CONH3 
during the fragmentation of DES and IDES. The loss of a neutral fragment maintains the 
cationic charge present at the quaternary nitrogen atom preserving DES/IDES ion 
response. The mechanism behind the loss of CONH3 could in a single step or by a two 
stage mechanism with the separate neutral loss of NH3 and CO as depicted below.   
 
CBA
NHCO    3  or CBA CONH    3  
 
In two step fragmentation mechanism the tandem MS data obtained on both analytical 
systems the peak for the intermediate B is not observed that indicates a rate limited 
fragmentation event followed by a rapid re-arrangement and subsequent fragmentation 
event which inhibits the detection of the intermediate compound. The elucidation of this 
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fragmentation mechanism could be achieved using a stable isotope labelled lysine 
standard with C13 substitution at the carbon associated with the carboxyl group or the 
carbon bound to the amino group to determine which carbon atom is lost in the CO 
fragment. Fragment 3 in Figure 2.5 corresponds to the loss of the nitrogen bound side-
chain (C4H8CH(NH2)COOH, m/z 130.0868) during the accurate mass measurement a 
peak is observed at m/z 397.2073. The hypothesis is the substitution of side chain with a 
hydrogen atom maintaining the quaternary status of the nitrogen atom. 
 
2.4.3. UHPLC-IM-MS analysis of healthy and COPD urine 
 
The UHPLC-IM-MS determination of free DES/IDES was assessed using pooled 
samples of healthy male urine, healthy female urine and COPD patient urine. Pooled 
healthy urine samples (three male and three female subjects) were selected based upon 
their creatinine content (3-15 mmol/L and 3-8 mmol/L for males and females 
respectively). These were chosen to represent the variation of urinary creatinine between 
individuals.
32
 The pooled COPD urine samples (5.8 mmol/L) consisted of six individuals 
(both male and female) with a range of COPD diagnoses ranging from moderate to severe. 
The extracted ion chromatograms (m/z 526) for the analysis of a pooled COPD urine 
sample are shown in Figure 2.5.  
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Figure 2.5. MS analysis of pooled COPD urine (a) SIC for m/z 526.2877 ± 0.05 Da in 
UPLC-MS mode, (b) associated UHPLC-MS spectrum at 50% IDES peak. (c) SIC 
for m/z 526.2877 ± 0.05 Da in UHPLC-IM-MS mode (bin range 110-113), (d) 
associated UHPLC-IM-MS spectrum at 50% IDES peak. 
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The retention times for free DES/IDES in the urine extract were slightly shorter than 
observed for DES/IDES standards under identical conditions. The assignment of the 
peaks at retention times of 3.0 and 3.3 minutes for DES and IDES respectively was 
confirmed by a standard addition of DES/IDES to a healthy urine sample. The DES/IDES 
peaks in the spiked healthy urine sample eluted from the column earlier (by 
approximately 30 seconds) than DES/IDES standards that were run before and after the 
spiked urine (data not shown). The result indicates that the urine matrix has a significant 
effect on free DES/IDES retention. However, the DES and IDES retention times were 
consistent for all the urine samples analyzed, with co-elution of IDES/IDES-d9, and the 
analyte resolution was still achieved, making quantitative measurements possible using 
the IDES-d9 internal standard.  
The selected ion chromatogram shown in Figure 2.5a represents an acquisition where the 
ion mobility data (TOF scans/bins 1-200) have been combined, generating a response 
equivalent to UHPLC-MS without ion mobility separation. Figure 2.5c illustrates the 
selected ion response in UHPLC-IM-MS mode, where a five bin window (TOF 
scans/bins 115-120, td 7.36-7.68 ms) was selected, showing a comparable signal to noise 
ratio. The effectiveness of the ion-mobility separation is illustrated in Figure 2.5b and 
2.5d which shows the mass spectra corresponding to UHPLC-MS and UHPLC-IM-MS 
analyses at the retention time for DES. The intensity of the DES ion (m/z 526) in the IM-
MS spectrum is enhanced relative to matrix ions, demonstrating that ion mobility based 
separation combined with MS can improve mass spectral quality. 
An on column LOQ of 0.61 ng and 0.55 ng of DES/IDES equivalent to 0.98 μg/g 
creatinine and 1.07 μg/g creatinine (assuming 5 mmol/L creatinine) in urine was achieved 
for all three urine samples following the SPE pre-concentration and clean-up described in 
Section 2.3.5, and UHPLC-IM-MS analysis. Data were normalized to creatinine 
concentrations in pooled urine samples (to adjust for individual glomular filtration rates), 
which were determined by UV ion-exchange chromatography (Section 2.3.6). 
Concentrations of free DES/IDES (μg/g creatinine) are shown in Figure 2.6.  
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Figure 2.6. DES/IDES concentration (µg/g creatinine) in pooled healthy female, 
pooled healthy male and pooled COPD urine (n=6).  
 
The quantitative UHPLC-IM-MS analysis shows comparatively higher levels of free 
DES/IDES in COPD urine than control (male and female) urine with increases in 
concentration of 79% and 74% respectively. These results indicate the potential clinical 
applicability of the UHPLC-IM-MS method for the distinction of healthy and COPD-
affected individuals using DES and IDES as urinary biomarkers, potentially enabling 
targeted treatment strategies based on individual patient need. 
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2.5. Conclusions 
 
The development of a UHPLC-IM-MS method is reported for the rapid separation (Rs > 
1.5) and determination (6 minute analysis time) of the elastin cross-linking molecules 
DES and IDES, using ion-pair chromatography under isocratic conditions, with good 
precision (< 4% RSD, n =9). The method has been applied to determination of free 
DES/IDES in pooled urine samples obtained from healthy and COPD-affected 
individuals, using isotope dilution with IDES-d9 and minimal sample preparation. Ion 
mobility-based separation enhanced the mass spectral ion intensities of DES/IDES and 
IDES-d9, relative to matrix ions, compared to UHPLC-MS without ion mobility 
separation, reducing non-target interferences and allowing urine samples from healthy 
and COPD-affected individuals to be distinguished based solely upon free DES and IDES 
levels. The method shows increased throughput and selectivity, applicable to the rapid, 
non-invasive biomarker screening in a clinical setting, and demonstrates the future 
potential of IM-MS for quantitative bioanalysis. Finally accurate mass UHPLC-MS/MS 
has been employed on fully resolved DES/IDES and propose the alternate loss of CONH3 
not COOH as previously published based upon accurate mass measurements on two 
separate instruments, although the fragmentation mechanism is as yet unknown.    
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CHAPTER THREE 
 
Direct extraction of urinary analytes 
from undeveloped reversed-phase thin 
layer chromatography plates using a 
solvent gradient combined with on-
line electrospray ionization ion 
mobility-mass spectrometry 
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3.1. Introduction 
 
Human bio-monitoring of urine has been shown to provide information relating to 
patients’ health without the need for invasive sampling techniques,1 but the use of direct 
mass spectrometric analysis is limited by the high concentrations of urinary salts.
2
 A thin-
layer chromatography (TLC) separation provides a simple and effective clean up for the 
identification of target urinary analytes
3
 and the hyphenation of TLC with mass 
spectrometry (TLC-MS) has been extensively investigated, using a wide range of ambient 
ionization techniques that allow the characterisation of analytes from solid surfaces.
4,5
  
The surface sample probe (SSP) interface, first developed by Busch et al allows the 
combination of an off-line TLC separation with continuous flow electrospray ionization 
(ESI) source.
6
 SSP employing a liquid microjunction (LMJ) was reported by Van Berkel 
et al. for the extraction of target analytes from a TLC plates following chromatographic 
development.
7
 The LMJ-SSP uses a coaxial design with inner and outer capillary tubes 
separated by an annular space. The outer capillary delivers a radial flow of the extracting 
solvent to the TLC plate to form a microjunction, and the inner capillary transports the 
extracted analytes to the ESI source. The advantage of the LMJ method is that the probe 
can ‘scan’ the TLC plate providing spatial information.8 However, the radial flow of 
eluting solvent is known to cause diffusion of the targeted analytes away from the inner 
sampling capillary and is only suitable for the analysis of reversed-phase (RP) TLC 
plates.
9
 
An alternative extraction system, developed by Luftman et al. uses a sealing SSP probe 
(S-SSP).
10
 The S-SSP has a ring shaped cutting edge that pierces the sorbant bed to form 
a tight seal to inhibit radial diffusion. The sampling probe head uses a parallel capillary 
system in which the eluting solvent is pumped across the target area to an extraction 
capillary at the opposite end of the probe. The S-SSP has been applied to the extraction of 
a wide range analytes from developed TLC and HPTLC plates, including: caffeine, 
ergotamine and metamizol in pharmaceutical formulations,
11
 multiple vitamins in 
commercially available energy drinks,
12
 isopropylthioxanthone in dairy products,
13
 and 
bioluminescent metabolites in marine sponges.
14
 The continuing development of SSP 
devices has resulted in the first commercially available S-SSP-TLC-MS interface.
15
 The 
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advantage of these direct solvent extraction techniques is the reduction in sample 
preparation steps prior to analysis, compared to established ‘scrape and elute’ techniques 
for the analysis of TLC spots.  
The direct extraction of analytes from developed and undeveloped TLC plates has been 
studied using desorption electrospray ionization (DESI).
16
 Active pharmaceutical 
ingredients (APIs) were separated from complex formulations using ion mobility-mass 
spectrometry (IM-MS).
17
 The addition of an ion mobility separation enabled 
deconvolution of the complex MS data, providing base peak ion responses for selected 
analytes both with and without the development of the TLC plate. A solvent gradient was 
incorporated into the DESI solvent flow to determine the optimum solvent composition 
for desorption. The success of this approach indicates that changing the solvent 
composition during elution has the potential to fractionate a mixture of compounds 
spotted on a RP-TLC plate without chromatographic development, due to their different 
affinities for the stationary phase. This paper describes the combination of a surface 
sample probe extraction with ESI-IM-MS for the direct on-line fractionation of urine 
from undeveloped RP-TLC plates using a gradient solvent extraction procedure. 
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3.2. Aims and Objectives 
 
 Interfacing a sealing surface sample probe (S-SSP) with ESI-MS for direct 
urinary profiling. 
 
 The use of undeveloped C18 TLC plates for S-SSP extraction of urine spots using 
a solvent gradient. 
 
 The improvement of profiling data due to the selective removal of the urinary 
salts by the gradient extraction. 
 
 Retain and separate the urinary analytes using a RP C18 phase and extraction 
using organic solvent gradient.  
 
 The addition of an ion mobility separation to further enhance the resolution 
achievable using the direct extraction technique. 
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3.3. Experimental 
 
3.3.1. Chemicals and Materials 
 
Analytical grade water, acetonitrile and dichloromethane were purchased from Fisher 
Scientific (Loughborough, UK). HPLC grade formic acid was purchased from Sigma 
Aldrich (Gillingham, UK). TLC Silica gel 60 RP-18 pre-coated plates (10 x 20 cm) with 
a RP thickness of 0.25 mm were purchased from Merck (Darmstadt, DE). 
 
3.3.2. Biofluid samples 
 
Urine samples (male and female) were provided by AstraZeneca (Charnwood, UK). 
AstraZeneca confirms that all ethical concerns have been addressed. The donated urine 
from healthy volunteers was combined and frozen at -80°C until required. Prior to 
analysis, samples were thawed on ice and required aliquots removed. The volume of raw 
urine was maintained at a total of 5 µL for each analysis. 
 
3.3.3. TLC plate preparation 
 
The raw urine (5 µL) was spotted in 1 µL aliquots onto RP-TLC plates that had 
undergone a two step cleaning process using water and dichloromethane. The spots were 
analysed without TLC chromatographic development. 
 
3.3.4. Solvent gradient extraction 
 
The organic solvent gradient was generated using a Waters AQUITY UPLC (Manchester, 
UK). The mobile phases consisted of 0.1% aqueous formic acid and acetonitrile (eluting 
solvents A and B respectively) at a flow rate of 0.2 mL min
-1
. A 6 minute gradient 
extraction programme was used for the analysis; 0-60% B (0-3 minutes), 60% B (3-4 
minutes), 60-0% B (4-5 minutes), 0%B (5-6 minutes). A 1 minute aqueous wash (0% B, 
0-1 minutes) was used prior to the gradient in some experiments. The direct loop 
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injection of raw urine (5 µL) was performed using a AQUITY UPLC autosampler at a 
flow rate of 0.2 mL min
-1
 and a solvent composition of 100% of 0.1% aqueous formic 
acid. 
 
3.3.5. TLC-MS interface 
 
The S-SSP-MS interface (CAMAG, Muttenz, CH) uses a pneumatic Luftman type S-SSP 
elution head connected in-line between the LC system and the ESI ion source of the IM-
MS spectrometer through a six point switching valve. The elution head forms a tight seal 
around the TLC zone of interest, inhibiting radial diffusion. The six point switching valve 
allows the LC flow to bypass the system or flow through the elution head when the S-
SSP is in contact with the TLC plate to extract target compounds from the surface. A 
nitrogen gas line, connected to the S-SSP system and maintained at a pressure of 45 psi, 
was used for the pneumatic movement of the S-SSP and cleaning of the sampling head. A 
schematic diagram of the S-SSP is shown in Figure 3.1. 
 
     
Figure 3.1. a) S-SSP in standby position with solvent flow direct to MS system, b) S-
SSP in extraction position with solvent flow directed through SSP head to extract 
surface-bound analytes and transport them to the MS system. 
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3.3.6. IM-MS conditions. 
 
IM-MS analyses were undertaken using a Waters Synapt HDMS spectrometer (Waters, 
Manchester, UK). The ESI source was operated in positive ionization mode with a 
capillary voltage of 3.2 kV and a cone voltage of 10 V. The source and desolvation 
temperatures were set to 150 °C and 350 °C, gas flow rates (N2) were set to 50 L h
-1
 and 
800 L h
-1
 respectively. The Tri-wave drift cell conditions were set at 24 mL min
-1 
drift 
gas (N2) with a travelling wave height/velocity of 8 V and 300 m s
-1
. IM-MS allowed the 
acquisition of nested mass spectra (0.065 ms scan 
-1
) and ion mobility spectra (13 ms scan 
-1
) that were processed using DriftScope and MassLynx 4.1 (Waters, Manchester, UK). 
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3.4. Results and Discussion. 
 
3.4.1. Solvent gradient extraction of urine. 
 
The direct analysis of raw urine spotted on an undeveloped RP-TLC plate was achieved 
by solvent extraction using a surface sampling probe combined with ESI-IM-MS. A 
comparison of the solvent gradient extraction of the urine from the surface of the RP-
TLC plate with direct LC loop injection into the ESI source is shown in Figure 3.2.     
 
 
 
Figure 3.2. Analysis of urine by ESI-MS. Overlaid total ion chromatographs (TIC) 
for (a) S-SSP solvent gradient extraction of urine (5 µL) spotted onto a RP-TLC 
plate without chromatographic development, (b) a 5 µL loop injection into the ESI 
source. 
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Figure 3.3. Summed MS data (6 min) from a) S-SSP solvent gradient extraction of 
urine (5 µL) spotted onto a RP-TLC plate without chromatographic development 
and b) a 5 µL loop injection into the ESI source. 
 
The solvent gradient extraction of urinary analytes from the RP-TLC plate (0-60% 
acetonitrile in 3 minutes) yields a greater total ion response than the direct loop injection 
of urine under identical conditions. The total ion intensity for the loop injection shows the 
highest response at 0.26 minutes. In contrast, the response for the gradient extraction 
from the undeveloped RP-TLC plate shows a broad peak between 1.1 and 4.7 minutes 
with a maximum response at 2.5 minutes. The greater response for the gradient extraction 
of analytes from the TLC plate (assuming 100% extraction efficiency), compared to 
direct loop injection of urine (Figure 3.2), indicates a reduction in ion suppression by the 
urine matrix, as the urinary salts elute from the TLC plate under the initial aqueous 
conditions, whilst other components are retained on the RP-TLC plate. Figure 3.3 
compares the MS data obtained from the gradient extraction of urine to the direct infusion 
of urine. The gradient extraction (Figure 3.3a) shows a greater number of urinary ion 
species with intensities in excess of the direct infusion spectra (Figure 3.3b).   
%
0
100
TOF MS ES+
4.85e4
114.06
144.00
136.05
129.02
170.09
157.08 229.15
219.05
189.05
173.05 214.09
199.18
286.20
236.03 265.12
310.20
302.23
312.22
413.26
329.99 352.11
m/z100 150 200 250 300 350 400
%
0
100
114.06
149.02
144.00
141.00
136.05
413.26
170.10
214.09
189.05
198.18
329.99311.98229.15
279.16 299.18
371.01 429.24
%
%
(a) 
(b) 
  102 
3.4.2. Analyte retention on the HPTLC plates 
 
The extraction method was modified to incorporate a one minute aqueous wash prior to 
the gradient extraction of the TLC plate (i.e. 100% aqueous formic acid for 0-1 minutes, 
0-60% acetonitrile for 1-4 minutes).The retention of urinary analytes on the TLC plate 
was confirmed by comparing the solvent gradient elution of a urinary component by the 
S-SSP-ESI-IM-MS from an undeveloped plate with, and without, the aqueous wash 
(Figure 3.4). 
 
 
 
Figure 3.4. S-SSP-ESI-MS solvent extraction of glucose (5 µL raw urine spotted 
onto an undeveloped TLC plate). Selected ion responses (m/z 181.07 ±0.05), a) 
without an aqueous wash and b) with a 1 min aqueous wash prior to gradient 
elution (0-60% acetonitrile). 
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The effect of the one minute aqueous wash prior to the start of the solvent gradient on the 
extraction of the analyte (identified as glucose, [M+H]
+ 
181.0719, mass error 3.8 ppm) 
was observed by comparing the selected ion responses for m/z 181.07 ±0.05 (Figure 3.4). 
The maximum response for glucose without the aqueous wash is at 1.7 minutes, but with 
the wash incorporated into the gradient, the glucose response peaks at 2.5 minutes. The 
difference between the extraction times of glucose with, and without, the wash prior to 
the gradient extraction (0.8 min) demonstrates the retention of glucose on the C18 RP-
TLC plate and its elution from the plate at a specific organic phase composition. Analysis 
of the ion responses and combined MS data indicated that the one minute aqueous wash 
offered no significant improvement in data quality when compared to the immediate start 
of the gradient. Subsequent gradient extraction experiments were therefore carried out 
without the additional 1 minute aqueous wash phase.  
 
3.4.3. Separation of urinary metabolites 
 
The solvent gradient extraction procedure was investigated further to determine the 
extent of analyte retention that could be achieved directly from an undeveloped RP-TLC 
plate. Figure 3.5 shows the ion responses for selected urinary analytes obtained from a 
solvent gradient S-SSP-ESI-IM-MS acquisition from an undeveloped plate. 
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Figure 3.5. S-SSP-ESI-IM-MS selected ion responses for three urine components 
extracted from an undeveloped TLC plate using solvent gradient extraction (a) m/z 
136.04, (b) m/z 286.20 and (c) m/z 198.22. 
 
The responses for known urinary components, creatinine (detected as [C4H7N3O + Na]
+
, 
m/z 136.04) and octenylcarnitine (detected as [C15H29NO4 + H]
+
, m/z 286.20), identified 
from their isotope patterns and accurate mass measurement, and an unidentified response 
at m/z 198.22, show maximum intensities at 0.3, 2.0 and 3.7 minutes respectively, that 
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were not observed in blank extractions. The extraction of these urinary components 
indicates different affinities for the C18 RP stationary phase, allowing a rapid partial 
separation of the analytes using a solvent gradient. Gradient extraction therefore enhances 
confidence in analyte identification, based on the separation of analytes enabling more 
accurate mass measurements to be obtained.  
The responses obtained by S-SSP show broad tailing peaks, which limits the degree of 
separation when compared to LC-MS analysis of excised TLC spots, but does not require 
lengthy chromatographic development or removal of target spots from the TLC plate, 
followed by off-line extraction, prior to analysis. The extent of separation obtained by 
direct gradient extraction from an undeveloped TLC plates is more comparable to 
fractionation on an SPE cartridge, but SPE is usually carried out off-line and requires a 
step-wise gradient elution resulting in multiple MS analyses to identify potential target 
analytes. The online S-SSP-ESI-IM-MS gradient elution also generates continuum data, 
rather than discrete data points obtained through an SPE fractionation, and therefore peak 
areas can be integrated enabling quantitative analysis. 
 
3.4.4. Incorporation of and ion mobility based separation 
 
The incorporation of an ion mobility-based separation using combined ion mobility-mass 
spectrometry (IM-MS) has previously been shown to enhance urinary metabolic 
profiling
17
 and was investigated in conjunction with the S-SSP extraction. The benefit of 
IM separation is illustrated in Figure 3.6.  
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Figure 3.6. S-SSP-ESI-IM-MS of urine from an undeveloped TLC plate. (a) 
Summed MS data gradient extraction, (insert) response in the region of m/z 198 
(gradient elution time 2-5 min) (b) ion mobility profile for the separation of 
unresolved ions at m/z 198.22 ±0.05 and associated mass spectra summed across bin 
numbers (TOF scans) (c) 31-38 and (d) 50-57. 
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The figure shows the unresolved response for a urinary component at m/z 198.22 and a 
background ion at m/z 198.19 in the solvent gradient elution time range of 2-5 min. The 
mass spectral resolution of the time-of-flight analyser (~ 7000 FWHM) is not sufficient 
to resolve these mass peaks (Figure 3.6a). The IM-MS mobility profile for m/z 198.22 
±0.05, shows two peak maxima at bins (TOF scans) 34 and 53, corresponding to ion 
mobility drift times of 2.21 ms and 3.45 ms respectively (Figure 3.6b). The 
corresponding mass spectra summed across bin numbers 31-38 (Figure 3.5c) and 50-57 
(Figure 3.6d) provide resolution of the two previously unresolved mass peaks. Without 
the additional resolving power that IM provides, these ions with similar nominal masses 
(±0.05) would be detected as a single component within the 198.22 ±0.05 mass window 
and potentially useful information lost. 
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3.5. Conclusions 
 
The direct solvent extraction of urine from the surface of undeveloped RP-TLC plates is 
demonstrated using a surface sampling probe with on-line gradient elution. The use of a 
solvent gradient for the on-line recovery of urinary analytes from TLC plates is shown to 
reduce ion suppression effects, providing better quality mass spectral data and allows 
fractionation of analytes based on their interaction with the C18 stationary phase. The 
incorporation of an IM separation is shown to enhance the gradient profiling technique 
providing structural information for the identification of unresolved mass ions. The direct 
S-SSP-ESI-IM-MS technique is a potentially powerful tool for the rapid profiling of other 
raw biofluids. 
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CHAPTER FOUR 
 
Direct detection of a sulfonate ester 
potentially genotoxic impurity by 
atmospheric pressure thermal 
desorption-electrospray-mass 
spectrometry 
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4.1. Introduction 
 
The ability to detect genotoxic impurities (GTIs) at low concentrations in active 
pharmaceutical ingredients (APIs) is of importance in the development of APIs.
1
 The use 
of sulfonic acids as counter ions during salt crystallisation can result in undesired 
reactions with alcohols to form sulfonate esters.
2
 The genotoxicity of sulfonic acid esters 
was reported by Glowienke et al. in 2005 based upon in-vitro salmonella reverse 
mutation (Ames)
3
 and micronucleus tests.
4
 The Ames test indicated that most sulfonic 
acid esters generated at least a two fold increase of revertants i.e. his- auxotrophs to his+ 
prototrophs in relation to controls. The micronucleus assay supported these findings with 
most compounds showing genotoxic properties due to the numbers of micronuclei 
(chromosomal aberrations) formed within the cultured mouse lymphoma cells (L5178Y) 
in comparison to controls.
5
 The US FDA and European EMA have established a 
threshold of toxicological concern (TTC) of 1.5 µg day
-1
 (1.5 ppm, assuming a daily dose 
of 1 g) for long-term treatments and a staged TTC where increased levels for limited 
periods are allowed for the purpose of drug development.
6
 The international conference 
on harmonisation; Q3A(RS) and M7 (step 2)
7,8
 has outlined the industry requirements for 
the qualification of GTIs in drug products. The pharmaceutical industry must demonstrate 
control and evaluation of raw materials (to a given threshold) that have the potential to 
form PGIs during drug production.
9-11
 The case for control of sulfonate salts can be 
exemplified by Nefinavir mesilate sold under the brand name of Viracept produced by 
Roche, where an error in production generated elevated levels of sulfonate esters in the 
final product which was subsequently withdrawn from the European markets.
12
  
The threshold limit applied to sulfonate esters has led to the development of several 
analytical approaches for the determination of these GTIs.
13
 The most widely used 
method is gas chromatography (GC) combined with mass spectrometry (MS)
14,15
 or 
flame ionization detection (FID).
16
 The derivatization of sulfonate esters prior to 
headspace GC-MS,
17-18
 and sample pre-concentration using solid phase micro-extraction 
(SPME)
19
 have also been employed to achieve the levels of sensitivity required. Other 
approaches include liquid chromatography-mass spectrometry (LC-MS) and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).
20-22 
The ability to accurately 
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detect the sulfonate esters is limited by their relative stability as the compounds may 
degrade during sample preparation leading to poor analytical sensitivity, therefore rapid 
detection of these compounds is of advantage. To date, the application of direct analysis 
techniques to the determination of GTIs in pharmaceutical formulations has received 
little attention. The mesylate, besylate and tosylate sulfonates are low molecular weight 
compounds with boiling points that are generally below 200 °C indicating that thermal 
desorption (TD) could be employed as a possible sampling mechanism. The potential of 
GTI detection by direct analysis was recently demonstrated by McCullough et al. 2011, 
using on-line extractive electrospray (EESI) sampling from a heated reaction mixture, 
where codeine was used as a surrogate GTI.
23
 
In this chapter, an in-house designed and constructed TD probe capable of heating solid 
and liquid samples to temperatures in excess of 350 °C was interfaced to a quadrupole-
time of flight-mass (Q-ToF) spectrometer. The desorbed methyl p-toluenesulfonate ester 
(MTS) vapour was detected as a sodium salt adduct ionized by extractive electrospray
24
 
in the presence of 0.01M sodium acetate. This novel approach to the direct detection of 
MTS in a surrogate API mixture (starch) is demonstrated to levels below a TTC of 1.5 
µg/g required by the FDA and EMA regulatory bodies. 
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4.2. Aims and Objectives 
 
 The application of thermal desorption combined with extractive electrospray for 
the direct analysis of volatile compounds. 
 
 Stabilisation of the known genotoxic impurity methyl-p-toluenesulfonate by the 
coordination with a metal salt cation. 
 
 The use of thermal desorption for direct detection of the genotoxic impurity from 
a surrogate active pharmaceutical ingredient matrix. 
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4.3. Experimental 
 
4.3.1. Chemicals 
 
Analytical grade water and methanol were purchased from Fisher Scientific 
(Loughborough, UK). HPLC grade formic acid, sodium acetate (≥99.0%), methyl p-
toluenesulfonate (≥97.0%) and potato starch were purchased from Sigma Aldrich 
(Gillingham, UK).  All chemicals were used without further purification. 
 
4.3.2. AP/TD probe 
 
A schematic diagram of the ion source region of a Waters Synapt HDMS spectrometer 
(Waters, Manchester, UK) modified for AP/TD-EESI-MS is shown in Figure 4.1 and 
images 4.2, 4.3 and 4.4. The TD probe was constructed by placing a cylindrical heater 
cartridge (2.5 mm o.d. x 50 mm; RS Components Ltd., Northants, UK) into a stainless 
steel tube (12 i.d. x 300 mm) with the heater positioned inside an aluminium adaptor at 
the probe tip. Samples were placed in a brass sample holder (o.d. 2.5 x 10 mm) located 
within the aluminium adaptor, with the base of the sample holder in direct contact with 
the heater cartridge. The sample holder was inserted through a hole in the side of a 
stainless steel tube (o.d. 12 x 50 mm) located between the ESI probe and the mass 
spectrometer inlet cone that spatially confines the thermally desorbed analytes for 
ionization by an in-line electrospray plume.  
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Figure 4.1. a) Diagram of the R-TD-EESI-MS ion source (not to scale) 
 
 
 
Figure 4.2. An image of the TD probe showing a) gas cooling system, b) heater 
regulation and c) TD probe tip.  
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Figure 4.3. a) A top-down image of the TD probe attached to the Synapt instrument 
using a stainless steel tube to confine the desorbed analytes, b) a side-on image of the 
TD probe tip showing the interface between the outer cone of the MS and the brass 
sample holder using the stainless steel tube.  
 
 
 
(a) (b) 
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Figure 4.4. A top-down image showing the alignment between the cones of the MS 
instrument, the TD probe and the ESI emitter. 
 
The cartridge temperature was set using a regulated temperature controller (Tempatron, 
Reading UK) capable of maximum operating temperature of 400 °C. The operating 
temperatures set to 250°C resulted in experimental temperatures of >190 °C within 2 
minutes. The AP-TD probe was cooled using a flow of air (10 L min
-1
) that was passed 
through a spiral of 1/8
th
 cooper tubing (Figure 4.3a.) contained within a polystyrene box 
that was packed with ice. The cooling system produced chilled air at approximately 10°C 
that was pushed though the TD probe flowing out around the sample holder. 
 
4.3.3. Sample preparation 
 
Methyl p-toluenesulfonate standards were prepared in methanol at concentrations of 0.5-
10 ng µL
-1
, MTS is genotoxic and should therefore be handled in low volumes within a 
fume hood using suitable personal protection, disposal was performed by incineration. In 
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the TD experiments MTS standards were placed into the sample holder and immediately 
introduced into the ion source. For surrogate API experiments 10 µL of standard solution 
was added to 50 mg of starch, equivalent to concentrations in the range 0.1-2 ppm (w/w), 
using aluminium foil sample wraps which were pre-prepared prior to analysis and placed 
into the sample holder. A small hole was made in the aluminium foil immediately before 
thermal desorption.  
 
4.3.4. EESI-MS conditions 
 
The EESI solvent consisted of 50:50 MeOH:H2O (v/v) modified with 0.1% formic acid 
(v/v) in initial studies and 0.01M sodium acetate (NaOAc) in all other investigations, 
which were infused from a syringe pump at a flow rate of 8 µL min
-1
. The mass 
spectrometer (Synapt HDMS, Waters, Manchester, UK) was operated in sensitivity (V) 
mode using positive ionization with a capillary voltage of 3 kV and a cone voltage of 20 
V. The source and desolvation temperatures were set to 150 °C and 120 °C, respectively, 
and the source gas flow rate (N2) was set to 20 L h
-1
. 
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4.4. Results and Discussion 
 
4.4.1. Stabilisation of MTS by coordination with sodium 
 
The application of atmospheric pressure thermal desorption-extractive electrospray-mass 
spectrometry (AP/TD-EESI-MS) to the analysis of a GTI with the thermal desorption 
probe introduced into the modified ion source region of the Q-ToF spectrometer was 
evaluated using methyl p-toluenesulfonate (MTS). The responses of the protonated and 
sodiated MTS ions generated by extractive electrospray
24
 were monitored during the 
introduction of thermally desorbed MTS vapour into the ion source. The mass spectra of 
MTS acquired using a methanol/water EESI plume with the addition of 0.1% formic acid 
(v/v) and 0.01M NaOAc as solvent modifying agents are shown in Figure 4.5. 
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Figure 4.5. Mass spectra obtained using thermal desorption of MTS vapour into the 
modified EESI ion source (50:50 (v/v) MeOH:H2O) with a) 0.1% formic acid (v/v) 
solvent modifier and b) 0.01M sodium acetate modifier. 
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Figure 4.5a shows the MTS response using 0.1% formic acid as the solvent modifier with 
the [M+H]
+
 ion at m/z 187.0440 (5.8 ppm mass error) present as the base peak. However, 
the protonated MTS fragments readily in the interface of the mass spectrometer yielding 
products at m/z 155, assigned to [MH-CH3OH]
+
, an unidentified rearrangement ion at m/z 
127 and the tropylium ion at m/z  91 which reduces the sensitivity for the [M+H]
+
 ion.  
The presence of an [M+Na]
+ 
ion in the mass spectrum (Figure 4.5a) indicates an 
ionization process involving conversion of a gas phase (neutral) MTS molecule into a 
sodiated gas phase ion by interaction with a solvent droplet containing traces of sodium 
in the EESI plume. The co-ordination of Na
+
 with tosylate molecules has been reported 
by Bai et al. who demonstrated that detection was improved by the formation of alkali 
metal adducts,
21 
Doping the EESI solvent with 0.01M sodium acetate yielded exclusively 
the [M+Na]
+
 ion for MTS (m/z 209.0258; 4.8 ppm mass error; Figure 4.5b). The absence 
of the [M+H]
+
 and its associated fragments in the mass spectrum improves analyte 
sensitivity increasing the mass spectral response by a factor of approximately 2 for the 
[M+Na]
+
 ion using 0.01 M sodium acetate compared to the formic acid doped EESI 
plume ([M+H]
+
 1131:1) and no fragmentation of the sodiated ion was observed. A 
sodium-doped EESI plume was used in all subsequent experiments. 
 
4.4.2. Thermal desorption probe heating profile 
 
The TD probe can achieve a temperature of approximately 200 °C in 2 minutes, which 
was found to be sufficient for the desorption of MTS vapour (Figure 4.6.). After reaching 
the maximum desorption temperature the probe was cooled by a flow of chilled air. The 
flow of cooling gas passed through the probe and exited at the probe tip, which rapidly 
cooled the sample holder to ambient temperatures with a total run time of 5 minutes. 
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Figure 4.6. Temperature profile of the TD probe developed for AP/TD-EESI-MS 
experiments. 
 
The AP/TD-EESI-MS analysis of MTS was carried out with the GTI spiked into 50 mg 
of starch to simulate the environment of an API. The samples were pre-prepared using 
sealed aluminium foil wraps that were pierced prior to analysis. The use of the disposable 
aluminium wraps prevented sample cross contamination and provided a rapid method of 
exchanging samples, reducing sample to sample cycle time to 6 minutes, which is 
significantly shorter than previously reported GC-MS and LC-MS run-times of 24 and 11 
minutes, respectively.
12,17
  
 
4.3.3. AP/TD-EESI analysis of MTS in a starch matrix 
 
The thermal desorption profile and mass spectrometric response obtained for the AP/TD-
EESI-MS analysis of MTS in starch is shown in Figure 4.7. 
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Figure 4.7. The AP/TD-EESI-MS analysis of MTS (2 ppm (w/w); 100 ng MTS in 50 
mg starch), a) total ion response, b) selected ion response for the sodiated MTS 
adduct ion (m/z 209.02 ± 0.02) and c) summed, background subtracted mass 
spectrum for MTS. 
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The total ion response for a 50 mg starch sample (Figure 4.7a.), used as a surrogate API, 
spiked with MTS at a level of 2 ppm initially increases with the probe temperature and 
then decreases when the heat is removed and the cooling gas flow initiated. The ion 
response returns to baseline levels within 4 minutes, but the temperature of the sample 
holder at this point is still too high to be handled (~ 70°C) and requires an additional 1 
minute of cooling. The selected ion response for the sodiated MTS ion ([M+Na]
+
, 209.02 
± 0.02) is shown in Figure 4.7b. The volatility of the MTS provides a sharp desorption 
peak, with a peak width at half height of 15 seconds. The maximum response for MTS is 
observed at 0.9 minutes when the TD probe temperature was at approximately 100°C. 
The MTS response returns to baseline levels within 3 minutes. The mass spectrum 
obtained from the MTS desorption peak is shown in Figure 4.7c. The background 
subtracted spectrum, averaged across the peak at half height, shows a base-peak response 
for the sodiated MTS ion (7.7 ppm mass error). The application of AP/TD-EESI-MS 
removes the requirement for lengthy sample preparation and derivatisation steps 
associated with other MTS detection techniques,
15,16
 because low volatility APIs will not 
be desorbed by TD, and sample throughput is maximised by reducing total analysis time 
and using disposable sample holders.  
The AP/TD-EESI-MS technique has a limit of detection (S/N 3:1) at 0.1 ppm (0.1 µg/g), 
which is 15 times lower than the limit set by the FDA and the EMA allows the detection 
of MTS (3:1, signal:noise) (Figure 4.8).  
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Figure 4.8. A LDR of the quantitative capability of the AP/TD-EESI-MS for the 
detection of MTS in a solid starch matrix (n=6). 
 
The correlation coefficient (R
2
 = 0.983) and the percentage relative standard deviation 
(%RSD) of 22% for the MTS peak areas at the 0.1 ppm level, are affected by the 
requirement to remove and replacement of the TD probe in the AP/TD-EESI source for 
each individual sample. The %RSD and linearity values are acceptable for such a manual 
analytical technique, used without an internal standard, but they do not yet meet the 
requirements for the use of the AP/TD-EESI-MS technique for quantitative 
measurements.
25
 The direct analysis method exceeds the detection requirements for MTS, 
indicating its potential as a rapid screening procedure based on a limit test to show that 
the MTS is below the TTC level. This application would be a useful indicator of the 
presence/absence of a potential impurity which could then be determined quantitatively 
using a well established technique as GC-MS. 
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4.5. Conclusions 
 
The direct detection of MTS in a surrogate API matrix is demonstrated using a TD probe 
combined with electrospray-mass spectrometry. This direct, ambient ionization approach 
offers reduced sample preparation and analysis times compared to previous GC and LC 
techniques, enabling high throughput analyses. The thermal desorption of MTS from a 
surrogate API matrix and co-ordination with sodium to form a stable vapour-phase 
sodium adduct ion provides levels of sensitivity that are greater than the regulatory 
requirements for this GTI. The technique has potential application to the screening of 
APIs for MTS, and potentially other alkyl sulfonate esters, formed during the 
pharmaceutical manufacturing processes.   
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CHAPTER FIVE 
 
Rapid determination of urinary 
creatinine levels by in-situ 
derivatisation-thermal desorption-
ion mobility-mass spectrometry 
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5.1. Introduction 
 
Thermal desorption is a commonly used method for the generation of a gaseous phase 
analyte (discussed in section 1.2.4). The process of directly heating a sample to liberate 
target molecules from the liquid phase has been predominantly applied to the analysis of 
volatile organic compounds (VOCs) by headspace gas chromatography (GC).
1
 Other 
applications of thermal desorption include headspace analysis by mass spectrometry 
(MS)
2
 and narcotic/explosive detection by ion mobility (IM) spectrometry.
3
 The 
application of thermal desorption is limited by the volatility of the target analyte, which 
can be altered by specific derivatisation reactions.
4-6
 
Most of the derivatisation reactions used in mass spectrometric sample preparation 
substitute a hydrogen atom present on a polar functional group of a molecule with a non-
polar motif.
4
 The substitution reactions of alkylation, acylation and silylation
5
 can 
significantly reduce the temperatures required for thermal desorption of a molecule. 
These reactions generally require a non-aqueous environment which promotes their use 
for GC based analyses, but limits their application to aqueous samples. The process of 
removing the water from a sample prior to derivatisation enables a wider range of 
derivatisation reactions to be conducted, but significantly increases the sample 
preparation time required. The use of aqueous based derivatisation reactions the 
difficulties regarding water containing samples, allowing direct derivatisation.
6
 The use 
of aqueous derivatisation reactions for the detection of compounds in urine has been an 
area of significant interest, particularly in the analysis of drugs of abuse,
7-8
 but the 
technique is still in its infancy for biomedical prognostic/diagnostic applications.
9
  
Urine is commonly analysed by high performance liquid chromatography (HPLC) and 
GC, hyphenated with MS, for the detection of excreted metabolites relating to disease 
states such as lung disorder,
10
 diabetes
11
 and cancer.
12
 These types of analyses have high 
sensitivity with good prognostic capabilities, but are limited by ion suppression effects 
due to the high salt content of urine
13
 and the requirement to normalise the target ion 
response to the excretion of creatinine.
14
 The normalisation process allows the absolute 
amount of an excreted metabolite to be expressed in relation to the creatinine level (i.e. 
µg/g creatinine) which can then be used as a comparison against a healthy population. 
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The concentration of creatinine in both urine and blood serum is dependent on several 
variables, including glomerular filtration rate, which is itself dependent on age, gender 
and body size.
15,16
 The measurement of an individuals creatinine clearance rate (CrCl), 
which is the amount of creatinine passed in 24 hours, determines the glomerular filtration 
rate (GFR), providing information on kidney function. 
A variety of methods are available for the determination of creatinine (Figure 5.1.) in 
urine,  
 
 
 
 
 
 
 
 
 
Figure 5.1. The resonance structures of creatinine. 
 
The most widely used method of creatinine quantitation is the Jaffe reaction.
17
 This 
colorimetric based approach places serum or urine in an alkaline environment to generate 
a reaction between creatinine and picric acid forming red/orange crystals. The non-
specificity of the Jaffe reaction limits its use, particularly in serum, and has therefore 
been modified numerous times to increase the accuracy of the technique.
18
 Other methods 
include a two-step enzymatic digestion of creatinine,
19
 which has higher selectivity 
compared to the Jaffe reaction but is limited by the multiple step sample preparation 
procedure and ion exchange chromatography. Creatinine quantitation in urine and serum 
by isotope dilution, derivatisation and GCMS has also been reported. The creatinine and 
creatinine-
13
C internal standard were dervatised to the corresponding glycine ethyl esters 
and fragmented by MS/MS forming alternate heavy and light fragments which enables 
accurate quantitation.
20
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The direct determination of urinary creatinine levels by extractive electrospray-tandem 
mass spectrometry (EESI-MS/MS) in the presence of a deuterated internal standard has 
been reported.
21
 The approach shows that ambient ionization can be used to measure 
urinary creatinine with high sensitivity. However, this approach does not separate the 
target analyte from the complex matrix prior to ionization and will be susceptible to 
interference from the matrix background. Incorporation of a derivatisation step enables 
specific functional groups to be targeted enabling preferential thermal desorption of a 
target molecule, whilst discriminating against the urinary salts and other underivatised 
metabolites. The combination of a rapid aqueous phase derivatisation to promote 
desorption of creatinine directly from the urine matrix, combined with EESI of the 
volatile derivatives, is demonstrated to provide an ambient ionization method for the 
direct quantitation of urinary creatinine unaffected by ion suppression from salts in the 
urine matrix. 
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5.2. Aims and Objectives 
 
 Develop a derivatisation reaction for urinary creatinine using acetic anhydride. 
 
 Employment of a thermal desorption step for the near instantaneous acylation of 
creatinine. 
 
 Assessment of the volatility of the mono-acylated creatinine molecule.  
 
 Confirmation of creatinine detection by ion mobility drift times and tandem mass 
spectrometry. 
 
 The direct determination of urinary creatinine levels by reactive thermal 
desorption combined with extractive electrospray-ion mobility-tandem mass 
spectrometry.   
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5.3. Experimental. 
 
5.3.1. Chemicals 
 
Analytical grade water and methanol were purchased from Fisher Scientific 
(Loughborough, UK). HPLC grade formic acid, acetic anhydride (99%) and creatinine 
(98%) were purchased from Sigma Aldrich (Gillingham, UK).  Creatinine-d3 was 
purchased from Toronto Research Chemicals Inc (Ontario, CA). All chemicals were used 
without further purification. 
 
5.3.2. AP/TD probe 
 
A schematic diagram of the ion source region of a Waters Synapt HDMS spectrometer 
(Waters, Manchester, UK) modified for direct on-probe derivatisation (R-TD-EESI-MS) 
is shown in Figure 5.2 The TD probe was a modified version of the probe previously 
described (section 4.3.2.) constructed by placing a cylindrical heater cartridge (2.5 mm 
o.d. x 50 mm; RS Components Ltd., Northants, UK) into a stainless steel tube (12 i.d. x 
130 mm) with the heater positioned inside an aluminium adaptor at the probe tip. 
Samples and the derivatisation reagent were injected into the brass sample holder (o.d. 
2.5 x 10 mm) located within the aluminium adaptor, with the base of the sample holder in 
direct contact with the heater cartridge. The sample holder was inserted through a hole in 
the side of a stainless steel tube (o.d. 12 x 50 mm) located between the ESI probe and the 
mass spectrometer inlet cone that spatially confines the thermally desorbed analytes for 
ionization by an in-line electrospray plume. The cartridge temperature was set using a 
regulated temperature controller (Tempatron, Reading UK) capable of maximum 
operating temperature of 400 °C. The operating temperatures set to 175°C resulted in 
experimental temperatures of >100 °C. The AP-TD probe was cooled post analyses using 
a flow of chilled air (10 L min
-1
 at 10 °C) through the probe. 
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Figure 5.2. Diagram of the R-TD-EESI-MS ion source (not to scale). 
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Figure 5.3. The modified TD probe, with a reduced probe length (130 mm) allowing 
the alignment of the TD probe to be fixed.  
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Figure 5.4. a) Face-on view of the modified TD probe interface for liquid injections 
b) side-on view showing the liquid injection process. 
(a) 
(b) 
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5.3.3. Sample preparation 
 
Creatinine standards were prepared in water at concentrations of 2.5-20 µg/mL (60 µL). 
Urine samples were diluted 1:100 with water and, deuterated creatinine-d3 was added at a 
concentration of 5 µg/mL (40 µL). In preliminary creatinine acylation experiments urine 
samples were mixed with acetic anhydride (100 µL) at a ratio of 1:1 to initiate the 
acylation reaction. The samples were heated to 50 °C and continually agitated throughout 
the 3 hour reaction period, 10 µL sample aliquots of the reaction mixture were diluted 
(1:10 with 50:50 MeOH:H2O + 0.1% formic acid) prior to direct infusion ESI-MS. On-
probe derivatisation was carried out by the direct injection of a 1:1 mixture of urine 
containing the creatinine-d3 internal standard, and acetic anhydride (10 μL) into the 
sample holder of the TD probe, which was pre-heated to 100° C.   
 
5.3.4. EESI-IM-MS/MS conditions 
 
The EESI solvent consisted of 50:50 MeOH:H2O (v/v) modified with 0.1% formic acid 
(v/v), which were infused from a syringe pump at a flow rate of 10 µL/min. The mass 
spectrometer (Synapt HDMS, Waters, Manchester, UK) was operated in sensitivity (V) 
mode using positive ionization with a capillary voltage of 2.8 kV and a cone voltage of 
15 V. The source temperature was set to 120 °C, with a nebuliser gas flow (N2). The 
quadrupole was set to transmit the mono acylated creatinine ([M+H]
+
 = m/z 156) and 
mono acylated creatinine-d3 ([M+H]
+
 = m/z 159) ions. The trap region of the Waters Tri-
Wave cell was set at 13 V to dissociate the acyl group from the creatinine and creatinine-
d3 molecules by CID. The travelling wave ion mobility (TWIM) cell wave height was 6 
V, the wave velocity was 300 m/s and the N2 drift gas was set to 30 mL/min. The ToF 
analyser scan time was 45 μs/scan. 
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5.4. Results and Discussion 
 
5.4.1. Creatinine derivatisation 
 
The aqueous derivatisation of urinary creatinine by acetic anhydride was tested using 
urine spiked with 100 µg of creatinine-d3. The resulting solution was mixed 1:1 with 
acetic anhydride and allowed to react at 50 °C for 3 hours. This solution was then diluted 
1:10 in 50:50 MeOH:H2O + 0.1% formic acid and directly infused into the ESI source of 
the mass spectrometer. The [M+H]
+
 responses for the mono-acylated urinary creatinine 
and creatinine-d3 were observed at m/z 156 and m/z 159 respectively (Figure 5.5) and 
selected for collision induced dissociation (CID). The fragmentation of the mono-
acylated creatinine resulted in the formation of fragment ions at m/z 114 and 117, 
corresponding to protonated creatinine and creatinine-d3 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. ESI-MS/MS spectrum showing the CID fragmentation of the [M+H]
+ 
 
ions of mono-acylated creatinine and creatinine-d3 (m/z 156 and 159 respectively) 
generating the creatinine and creatinine-d3 product ions at m/z 114 and 117. 
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The loss of the acyl group from the mass-selected mono-acylated creatinine and 
creatinine-d3 precursor ions (m/z 156 and m/z 159) by CID provides greater selectivity for 
the  identification of the target analyte and internal standard compared to the direct 
detection of the mono-acylated ions.  
 
5.4.2. Rapid on-probe creatinine derivatisation 
 
The direct on-probe mono-acylation of urinary creatinine was tested on the TD probe to 
determine how the addition of the acyl group to the creatinine molecule affects its 
volatility. An aliquot of underivatised urine was directly injected into the pre-heated 
sample holder, followed by second aliquot that had been mixed 1:1 with acetic anhydride. 
The results are shown in Figure 5.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Selected ion responses obtained from on-probe R-TD-EESI-MS analysis 
of a) mono-acylated urinary creatinine (m/z 156) and b) the protonated creatinine 
CID fragment (m/z 114) with and without derivatisation with acetic anhydride. 
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Figure 5.6 shows that the presence of the acetic anhydride derivatisation reagent is for the 
detection of urinary creatinine at 100 °C as only a small response is observed for the 
undervatised sample. The dervatised urinary creatinine injection gives a strong response 
for the mono-acylated creatinine [M+H]
+
 at m/z 156 and the creatinine fragment ion at 
m/z 114. These result indicate that the mono-acylation of creatinine significantly 
increases the compound volatility from 300 °C in the underivatised state to less that the 
TD probe temperature of 100 °C, and that the reaction is sufficiently rapid to allow direct 
on-probe derivatisation and thermal desorption.      
 
5.4.3. Selectivity for the identification of creatinine 
 
Typical data obtained from the R-TD-EESI-MS/MS analysis of urine containing 
creatinine and creatinine-d3, and incorporation an ion mobility separation after mass-
selection of the mono-acylated ions and before tandem mass spectrometry is shown in 
Figure 5.7. 
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Figure 5.7. R-TD-EESI-IM-MS/MS selected ion responses from the analysis of urine 
post CID a) creatinine fragment b) creatinine-d3 fragment c) summed MS data full 
width half height (FWHH) and d) IM drift profile for urinary creatinine. 
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The selected ion responses for the protonated creatinine (m/z 114) and creatinine-d3 (m/z 
117) fragment ions (Figures 5.7a and 5.7b), from the R-TD-EESI-IM-MS/MS analysis of 
the mass-selected mono-acylated urine acylated creatinine-d3 molecules, shows the 
effective fragmentation of the acyl derivatives at m/z 156 and m/z 159. The mass 
spectrum obtained by averaging spectra across the width of the SIR peak at half height 
(Figure 5.7c) shows the protonated creatinine and creatinine-d3 fragment ions. The 
identification of creatinine was confirmed by accurate mass measurement, giving a mass 
accuracy of 3.5 ppm for the [M+H]
+
 creatinine response (m/z 114.0663) using creatine-d3 
as reference standard. The insert (Figure 5.7d) shows the mass-selected ion mobility 
spectrum for the urinary creatinine molecule. The drift profile is defined by the collision 
cross section of the ion (i.e. size and shape) as it passes through a drift region against an 
opposing of flow of buffer gas (N2) under the influence of an electric field.
24
 The drift 
profile for the urinary creatinine, with the peak maximum at scan/bin 36 corresponds to a 
drift time of 1.6 ms that matches the drift time obtained from creatinine standards. The 
combination of tandem mass spectrometry with high resolution and the ion mobility 
separation provides selectivity that supports the use of the direct derivatisation R-TD-
EESI-IM-MS/MS approach for the rapid determination of urinary creatinine. 
 
5.4.4. Quantitation of creatinine levels by R-TD-EESI-IM-MS/MS 
 
The calibration graph obtained for the R-TD-EESI-IM-MS/MS quantitation of creatinine 
standards (2.5-20 µg/mL each spiked with a constant 5 µg/mL creatinine-d3) based on the 
peak area ratio from six replicate injections for each point in the calibration curve shown 
in Figure 5.8. 
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Figure 5.8. A calibration curve based upon the ratio of peak areas (creatinine: 
creatinine-d3, from ion mobility bins 35-37) obtained from direct derivatisation R-
TD-EESI-IM-MS/MS (n=6). 
 
The correlation coefficient for the calibration curve was 0.986 demonstrating the linearity 
of the response from the direct analysis technique. The limit of detection (LOD) based 
upon six replicate injections at 5 µg/mL was 0.4 µg/mL (signal:noise, 3:1) and the limit 
of quantitation (LOQ) was determined to be 1.35 µg/mL (signal:noise, 10:1). The intra-
day repeatability was determined using %RSD from the ratios of replicate injections that 
ranged from 8-10% over the six replicate injections at each concentration. 
 
5.4.5. Determination of urinary creatinine by R-TD-EESI-IM-MS/MS 
 
The determination of urinary creatinine was performed using aliquots of diluted urine 
samples (diluted 1:100 in H2O). The resulting solutions were mixed 1:1 with acetic 
anhydride prior to injection and analysis by R-TD-EESI-IM-MS/MS.  
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Figure 5.9. The selected ion responses for a) urinary creatinine fragment (m/z 114) 
and b) creatinine-d3 fragment (m/z 117) from six replicate injections of a 1:1 mixture 
of urine, spiked with creatinine-d3, and acetic anhydride using the R-TD-EESI-IM-
MS/MS method. 
 
Figure 5.9 provides an example of the SIR responses for the urinary creatinine and 
creatinine-d3 fragments obtained from the R-TD-EESI-IM-MS/MS analysis. The thermal 
desorption process generates sharp desorption profiles with high intensity. The peaks 
obtained show peak widths of <15 s. The peak tailing does not limit sample throughput 
with multiple injections separated by a 1 minute providing baseline signals for creatinine 
and creatinine-d3 prior to the following injection, demonstrating that there is no carry 
over between samples. 
The peak intensities of the urinary creatinine fragment and creatinine-d3 fragment ions at 
IM bins 35-37 vary from injection to injection due to small variances in sample heating 
and sample volume, but are effectively normalised by determining the peak area ratio 
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between the creatinine standard and the deuterated analogue. The normalisation of peak 
areas generates high precision data with typical inter-sample percentage relative standard 
deviation of 8-10% which is within the acceptable limits for accreditation as a 
bioanalytical screening procedure.
23
  
The precision data obtained from the six urine injections is provided in Table 5.1. 
 
Table 5.1. Precision creatinine quantitation data from diluted urine samples (n=6) 
Diluted Urine (1:100) 
Sample Peak Area 114  
(m/z) 
Peak Area 117  
(m/z) 
Ratio         
(114/117) 
1 8.477 3.988 2.126 
2 10.622 4.553 2.333 
3 10.282 4.942 2.081 
4 12.245 4.652 2.632 
5 8.244 3.213 2.566 
6 10.623 4.186 2.538 
Average 10.082 4.256 2.379 
Standard Deviation 1.5 0.6 0.24 
%RSD  9.9 
 
The six 1:100 diluted urine injections produced responses within the calibrated range 
with a mean creatinine concentration in the diluted urine, of 14.42 µg/mL. The dilution 
factor (1:100) provides a final concentration of 1.44 mg/mL, which is within the normal 
urinary creatinine range based upon the donor (healthy male, 30 years of age). The 
precision of the R-TD-EESI-IM-MS/MS technique is confirmed by the value obtained for 
the %RSD between the six urine samples calculated as 9.9%.  
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5.5. Conclusions 
 
The direct determination of urinary creatinine has been performed by a direct on-probe 
aqueous acylation prior to thermal desorption and EESI-IM-MS/MS. The rapid acylation 
of creatinine to its mono-acyl derivative increases the volatility of the molecule in the 
dervatised form enabling thermal desorption. The EESI-IM-MS/MS analysis provides 
selective target ion identification by fragmentation of the acyl derivatives, generating 
fragments with molecular ion responses, matching drift time profiles in IM and high 
resolution mass spectrometry. Quantification was carried out by the use of stable isotope 
dilution with creatinine-d3. 
The modified TD probe with the alignment of the system in a single fixed position 
provided highly reproducible data over the range of 2.5-20 µg/mL with %RSDs ranging 
from 8-10% for replicate injections. The direct analysis method allowed high sample 
throughput, with an injection to injection time of 1 minute. The urinary creatinine levels 
of six identical diluted urine samples were determined by the derivatisation R-TD-EESI-
IM-MS/MS method which provided a %RSD of 9.9%. The derivatisation/thermal 
desorption approach could be applied to other involatile compounds present in complex 
matrices through the application of target specific derivatising agents to promote 
volatility and desorption of a molecule, enabling direct quantitation whilst reducing 
background matrix interferences. 
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CHAPTER SIX 
 
Conclusions and further work 
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6.1. Thesis Overview 
 
6.1.1. Summary of Chapter One 
 
The introductory chapter one brings together the multi-disciplinary areas of investigation 
that are reported in the experimental chapters of this thesis. The introduction reviews the 
application of mass spectrometry for clinical based analyses and describes the current 
transition from the traditional use of immunoassays to mass spectrometry. Specific 
relevance is placed on the use of the ambient ionization techniques to provide 
information rapidly with minimal sample preparation prior to analysis and their 
application to clinical measurements. The theoretical aspects of the mass spectrometers 
and the hyphenated techniques of liquid chromatography and ion mobility that have been 
used in this thesis are discussed.      
 
6.1.2. Summary of Chapter Two 
 
The elastin degradation products, desmosine (DES) and isodesmosine (IDES) are highly 
stable, cross-linking amino-acids that are unique to mature elastin. The excretion of 
DES/IDES in urine, in the free form and with associated peptide fragments, provides an 
indicator of lung damage in chronic obstructive pulmonary disease (COPD). A 
quantitative ion mobility-mass spectrometry (IM-MS) method has been developed for the 
analysis of free DES/IDES in urine with deuterated IDES as an internal standard. 
Resolution of DES/IDES isomers was achieved in less than five minutes using ultra 
performance liquid chromatography (UPLC) combined with ion pairing. The optimized 
UPLC-IM-MS method provided a linear dynamic range of 10-300 ng/mL and a limit of 
quantitation of 0.028 ng/mL for IDES and 0.03 ng/mL for DES (0.55 ng and 0.61 ng on 
column respectively). The method reproducibility (%RSD) was < 4% for DES and IDES. 
The UPLC-IM-MS method was applied to the analysis of urine samples obtained from 
healthy volunteers and COPD patients. The DES/IDES concentrations in healthy and 
COPD urine showed an increase in DES (79%) and IDES (74%) in the COPD samples, 
relative to healthy controls. The incorporation of an IM separation prior to m/z 
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measurement by MS was shown to reduce non-target ion responses from the bio-fluid 
matrix. 
The future work in this area relates to the fragmentation process of  DES and IDES, the 
high resolution MS data reported in this thesis indicates that the currently accepted 
fragmentation pattern, obtained on low resolution instruments, for the loss of COOH is 
incorrect and the proposed loss of CONH3 is supported by the nitrogen rule and low ppm 
mass errors on the high resolution data. The re-arrangement enabling the loss of CONH3 
from the aliphatic chains behind this fragmentation pattern requires determination.  
 
6.1.3. Summary of Chapter Three 
 
The direct extraction of urinary analytes deposited on reversed-phase thin-layer 
chromatography (RP-TLC) plates is demonstrated using a solvent gradient extraction 
procedure without prior chromatographic development. The surface sample probe TLC-
MS interface used for the gradient extraction is compared to direct loop injection into the 
electrospray ion source for biofluid profiling. The gradient elution is shown to enhance 
ion intensities, as urinary salts are eluted in aqueous formic acid in the early part of the 
gradient reducing ion suppression. The retention of urinary components on the C18 RP-
TLC plate was confirmed by monitoring analyte responses with, and without, an aqueous 
wash phase prior to the solvent gradient extraction. The use of gradient elution allows 
fractionation of the complex biological matrix as a result of differential retention of urine 
components on the undeveloped RP-TLC plate. The direct gradient analysis of TLC 
plates has also been combined with ion mobility-mass spectrometry to further resolve the 
complex urinary profile and identify co-eluting compounds.  
The S-SSP was also used to extract whole blood from undeveloped TLC plates and 
comparable results to the extraction of urine have been obtained from a pilot study. This 
area requires further investigation to determine any potential benefits derived from the 
gradient extraction of blood compared to the use of dried blood spots.  
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6.1.4 Summary of Chapter Four 
 
A direct, ambient ionization method has been developed using atmospheric pressure 
thermal desorption-extractive electrospray-mass spectrometry (AP/TD-EESI-MS) for the 
detection of the genotoxic impurity (GTI) methyl p-toluenesulfonate (MTS) in a 
surrogate pharmaceutical matrix. A custom-made thermal desorption probe was used to 
the desorb and vaporize MTS from the solid state,  by rapid heating to 200 °C then 
cooling to ambient temperature, with a cycle time of 6 minutes. The detection of MTS 
using EESI with a sodium acetate doped solvent to generate the [MTS+Na]
+
 adduct ion 
provided a significant sensitivity enhancement relative to the [M+H]
+
 ion generated using 
a 0.1% formic acid solvent modifier. The MTS detection limit is over an order of 
magnitude below the long term daily threshold of toxicological concern (TTC) of 1.5 
µg/g and the potential for quantitative analysis has been determined using starch as a 
surrogate active pharmaceutical ingredient (API). 
The analysis of MTS using the AP/TD-EESI-MS could be repeated using an API matrix 
in replacement of the surrogate starch matrix used previously. The API matrix requires 
investigation as interactions between the matrix and the MTS compound may adversely 
affect the thermal desorption of the impurity.   
 
6.1.5. Summary of Chapter Five 
 
A direct, ambient ionization method has been developed using reactive thermal 
desorption combined with extractive electrospray-ion mobility-tandem mass 
spectrometry (R-TD-EESI-IM-MS/MS) for the determination of creatinine in urine. The 
volatility of creatinine was enhanced by a rapid on-probe aqueous acylation reaction, 
using a custom-made thermal desorption probe, allowing thermal desorption of the mono-
acylated derivative and extractive electrospray ion ionization. The mono-acylated 
creatinine [M+H]
+
 ion (m/z 156) was mass-selected and fragmented using MS/MS to 
remove the acyl group generating the protonated creatinine [M+H]
+
 product ion at m/z 
114, providing selectivity in the identification of creatinine. Stable isotope dilution with 
creatinine D3 was used for quantitative measurements. The direct on-probe derivatisation 
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allows for high sample throughput with a typical cycle time of 1 minute per sample. The 
method shows good linearity (R
2
 = 0.986) and repeatability (8-10% RSD) in the range 
2.5-20 µg/mL. The creatinine levels in a series of diluted (1:100) urine samples from a 
healthy individual were determined to contain a mean concentration of 1.44 mg/mL of 
creatinine with a precision (%RSD) of 9.9%.  
The approach of R-TD-EESI could be used in future studies to target other involatile 
species in the urinary metabolome with specific derivatisation reagents, and the potential 
application for the analysis of different biofluids. 
 
6.2. Thesis Conclusion. 
 
The experimental chapters provided in this thesis have assessed the use of high 
throughput technologies for the rapid analysis of samples enabling the generation of 
clinically relevant information. The benefits of employing the ambient ionisation 
techniques in the terms of reduction in sample preparation and removal of sample 
fractionation prior to analysis are supported by the variety of applications described in the 
experimental chapters. In each case the use of UHPLC, EESI and TD allowed the rapid 
generation of analytical data that is robust, reproducible and detectable at biologically 
relevant levels. The thesis supports the use of the ambient ionization methods in 
conjunction with traditional techniques as LC and GC to increase the toolbox available 
for the analytical chemist. Separations based solely on analyte polarity can be extended to 
include analyte volatility and solubility which can be further enhanced with the 
application of post ionization ion mobility separations.  
The current limitation for the uptake of the ambient ionization methods is in regards to 
standardization of the analyses as many ambient ionization sources used to date are in-
house designed and built. In the future these will require significant regulation in regards 
to the system optimisation and operation to normalize the way that analytical data is 
obtained. The ambient ionization techniques should not be viewed as specialized methods 
performed by few but moreover should be viewed as standard techniques as they require 
minimal operational expertise, but also provide an effective solution to low analytical 
throughput. 
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